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ABSTRACT
The mechanical environment of the cell is important for changes in behavior. Cellular behavioral
changes can be traced to gene expression profile changes. These effects were studied in the
context of Micromechanical force therapy, a novel therapeutic treatment in the management of
different types of wounds. The mechanism of therapies that work by applying suction pressures is
still not completely understood. It is proposed that micromechanical forces are the dominant
mechanism by which they obtain accelerated wound healing. However, these therapies don't only
impose forces to (wounded) tissue. They also remove edematous tissue as well as applies
hypobaric oxygen conditions to the tissue.
Therefore, it was decided first to study only the effects of pure forces on normal tissue. 50g forces
were applied to rat ears in vivo. The ears were then sampled over a period of time for their gene
expression profiles on Affymetrix RAE 230 2.0 gene chips. 8 time points were obtained for each
of control and stretch conditions. One rat ear was chosen to be control (and without stretch), the
other was stretched. A modified Gene set enrichment analysis (GSEA) on the expression profiles
was conducted using the paired difference t statistic squared as the ranking metric. A further
refinement which didn't use the sign of the t statistic looked at expression changes in either
direction (the combined analysis). Important genesets were obtained relevant to the differences
seen between control and stretch conditions.
In the combined GSEA analysis, hypoxia came to the top of the gene set list followed by
'response to mechanical stimulus'. To test the significance of this result, a permutation test was
conducted on the dataset. By shuffling the class (control versus stretch) labels randomly, different
permutations were created and the GSEA was run to see if the occurrence was a chance event.
The P values obtained were 0.001 and 0.014 showing that both were significant because they
were not enriched randomly.
The hypoxia geneset could be an important modulator of forces in wound healing. Future work
will test in a biological model the validity of the importance of hypoxia in this system.
Thesis Supervisor: Prof. Isaac Kohane
Lawrence J. Henderson Associate Professor of Pediatrics, Harvard Medical School & Harvard
MIT HST department, Director, Children's Hospital Informatics Program
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Chapter 1
Background and Introduction
This thesis seeks to understand the effects of forces on tissues and on wound healing, and
it deals primarily with effects and conditions that are of a mechanical nature. Therefore,
we will define this word. Some definitions that capture the essence of our usage are the
following (from Webster's online):
caused by, resulting from, or relating to a process that involves a purely physical as
opposed to a chemical change.
relating to, governed by, or in accordance with the principles of mechanics. [Mechanics
is...a branch of physical science that deals with energy and forces and their effect on
bodies]
In summary, mechanical deals with matter, and in this thesis we will use mechanical
rather broadly to imply "non-chemical". Mechanical energy is energy that matter has by
virtue of its position or its motion. Before we define our usage of mechanical forces, we
need to define forces and their types. A force is an influence that tends to change the state
of rest or motion of a body. There are two types of forces: Body forces (such as gravity),
and surface forces (such as contact forces between two bodies). We will mostly deal with
surface forces. We will define "mechanical forces" as forces caused by hydrostatic or
dynamic pressure (positive or negative), and forces caused by contact between two
physical entities (such as the skin on the hand and a doorknob).
A mechanical stimuli is thus a stimuli that is a fluidic pressure (or contact pressure) or
contact between two entities. Stress and strain can be considered to represent the
mechanical state of a body. They are related to each other through the intrinsic
mechanical properties of the body (such as Elasticity modulus, Poisson's ratio).
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Stress = E*Strain
As mentioned, we seek to understand the effects of forces on tissues and on wound
healing. To this end, we develop a progressively complex series of studies that seek to
show the effects of forces on tissues and wound healing.
Effects of forces
Why is it important, however, to understand effects of forces on tissues? It is well known
that cells respond to their chemical environment. For example, different autocrine,
paracrine, and endocrine molecules travel to the wound bed to effect the wound healing
response. This response is seen in the change in the gene expression profile of cells that
reside in the wound bed. However, this is not the end of the story. The mechanical
environment of the cell (comprising both the mechanical state of the cell surroundings
and mechanical stimuli to the cell) also causes a change in the gene expression profile of
resident wound cells.
For example, Lott-Crumpler [1] says that wounds heal better if their principal stresses are
minimized. And, in a recently submitted paper, Saxena et al have shown that the Vacuum
assisted closure device (or the VAC sponge)-we'll talk about the VAC device further
down in this chapter-works by optimizing the level of strain that wound cells are placed
under [2]. This device itself is one of a class of devices that we call a micromechanical
force therapy device (and henceforth we shall discuss the general MMF therapy devices).
A possible explanation that takes into account both these ideas could be that stresses
should be at an optimal level and not too high or too low.
Now that we've rationalized the importance of studying forces on tissues, we need to
decide on a model system which we can use to look at these effects. A literature search
was therefore conducted to see what types of models exist on forces and wound healing.
We describe these next under 'literature search'.
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Our lab has looked at the rat ear as a suitable model for the application of forces to
tissues. We decided to use this model for the forces on tissues study.
Importance of wounds
Worldwide, wounds pose a major health issue. Lower extremity ulcers alone cost the US
Medicare system $1.5 billion. Thus, unless wound therapies see a large improvement, we
will see escalating treatment costs as the population ages and as the incidence of diabetes
(which itself increases with the aging population) increases.
Importance of forces in the context of wounds
Cell proliferation and division are induced by the action of micromechanical forces.
Tissue expansion is used by plastic surgeons to expand soft-tissue envelopes in
reconstructive surgery, and distraction osteogenesis is used by orthopedic and
maxillofacial surgeons (based on Ilizarov's work) to increase the size of bones [3, 4].
Further, during morphogenesis, cell proliferation occurs in a site-specific manner in
response to local strain from tissue expansion, as happens in bud formation of glandular
branches or gyri formation in the brain. These proliferative changes help to sculpt tissue
architecture and shape organs [5]. Ingber et al. have shown that in order for cells to
respond to soluble mitogenic factors and proliferate, they have to extend, generating
isometric tension either by adherence to a stiff substrate or by external application of
mechanical forces. Cells that aren't able to extend assume a more spherical shape (e.g.,
by spatial restriction of cell spreading, or by growing on a malleable substrate that
cannotresist cell contractility and thus dissipates cell tension) become growth-arrested
and tend to become apoptotic [6], [7], [8].
Thus, cells recognize mechanical signals and in response increase their rates of
proliferation. We can think of this behavior as providing a natural mechanism for tissue
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homeostasis. Where tissue mass expands, cells are stretched and thus divide in response.
Further, our results suggest that the application of the MMF device exerts
micromechanical forces on individual cells in the wound bed, thus stimulating cell
proliferation and accelerating wound healing.
In previous in vitro work, it has been shown by Ingber and others that only cells allowed
to stretch can divide and proliferate in response to soluble growth factors (see Fig below),
whereas cells that are not stretched and assume a more spherical shape are cell-cycle
arrested and tend to undergo apoptosis [7], [6]. Directional growth of capillary sprouts is
also promoted by tension application in three dimensional angiogenesis models in vitro
[9]. Moreover, it is known that vascular endothelial cells express a different array of
genes depending on whether they were exposed to static, laminar, or turbulent flow [10],
[11], [12]. The figure below is reproduced from [2].
Microtubules Cell ffembrane
MIcroftments
ECM proteins 4 -mo Cell StretCh ".*
Schematic of a cell. The cytoskeleton is attached to a basement membrane. Cell stretch is effected by
attachment to the extracell matrix or by application of external force. Gene pathways are
hypothesized to be triggered by microfilament/microtubule deformations resulting from cell stretch.
It is apparent that cells are able to sense mechanical forces and respond through the
regulation of specific genes and the induction of cellular programs. The exact
mechanisms for these effects are not fully understood but likely are related to
conformational changes in the cytoskeleton in response to mechanical forces. We
hypothesize that the application of mechanical force to wounds induces tissue
deformation at the level of individual cells, leading to cell stretch, thereby providing a
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powerful mechanism for inducing cell proliferation and angiogenesis and hence
promoting wound healing.
We developed a finite element model to study the strains in wounded tissue. We found
that the simulated tissue under MMF therapy conditions had strains in the range of 5 to
20 percent depending on the parametrizations that were conducted (these mimicking the
stage of wound healing) that were similar to those seen in different tissues under optimal
conditions for growth [2], [6], [7]. This study is described in detail further down in the
thesis.
Other non-mechanical effects such as soluble growth factors and attachment to cells to
extracellular matrix proteins, even though essential, are not sufficient to stimulate cell
proliferation [5]. Progression of cell through its cell cycle also requires the appropriate
physical context to respond to these two chemical stimuli.
Other researchers have also shown that tissues need to be placed under specific strain
fields in order to regenerate. For example, Miyajima [13] has shown that osteoblasts
seeded in vitro show maximal growth at 17% strains, while Akhyari et al have shown
[14] that a 20% strain (or stretch) "enhanced the formation of a three-dimensional tissue-
engineered cardiac graft by improving the proliferation and distribution of seeded human
heart cells and by stimulation organized matrix formation resulting in an order of
magnitude increase in the mechanical strength of the graft."
However, this structural requirement may be absent in wounds, as the normal matrix is
degraded or altered such that it fails to form a mechanically continuous structure to
provide the scaffold on which cells normally stretch and build up isometric tension (for
example as may happen by stretching the scaffold through the remaining intact network
and also as may happen when cells become seeded onto the MMF therapy 'sponge'
material)-see the section below on forces are transmitted through the wound bed and the
Figure in the section.
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The mechanical strain generated by the MMF therapy in the microscopic tissue domains
may, in addition to other benefits of suction, overcome this loss of tissue integrity and
substitute for the missing structural basis necessary for cell proliferation.
A conceptualization of force-transmission to cells in the wound bed
Forces applied at boundary conditions always (unless there is rupture in the tissue)
translate to constant forces in all areas of the wound bed (at steady state conditions).
Weaker region of
the wound bed
Stronger region of
the wound bed
Cell
attached to
matrix
Artificial
substrate used
to impose
strains
growing matrix
composed of
collagen and
elastin
Possible rupture in the weaker part of wound
bed results in zero strain transmission to the
cell
Optimally, we'd like to impose a constant strain at each micro loci, as it is optimal strains
that are critical for cells to proliferate and divide. These optimal strains do not necessarily
have to be constant across different areas of the wound bed-they may for example be
lower for regions that have a lower modulus of elasticity or weaker strength. In other
words, the tissue will display non-homogeneous behavior in terms of material properties.
This could for example be because if the tissue at the weaker spots is less elastic, it may
rupture bringing the strains to zero, even though the applied strains through a scaffold
may seem to be non-zero.
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When an external global force is input, the force has to be lower than the yield stress of
the weakest area of the wound bed. Otherwise the force will cause that area to expand
until it breaks, and that will stop any further force transmission through that axis.
It may also happen that the 'lodging' of the ruptured or wounded tissue within the
'lattice' network of the sponge may facilitate the transmission of forces to tissue (and
therefore to cells) that makes up the wound bed.
Thus the MMF therapy sponge-which we'll talk about next-facilitates force
transmission by in essence providing a scaffold onto which the (at least the) surface areas
of the wound bed can 'lodge' on and which then when subjected to a negative pressure
are 'pulled' inward into the sponge-the sponge providing contact points where
resistance 'supports' the wound surface creating continuities that may possibly have been
broken because of the rupture in the intact tissue scaffold.
(One of) the model systems that we used to study these force effects is
Micromechanical force therapy (MMF therapy)
A device that is now commonly used in wound closure clinical applications is the
Vacuum Assisted Closure Therapy (VAC) device (KCI, San Antonio, Texas)-one
device in the general class of MMF therapy devices. The VAC is a relatively new
therapeutic paradigm. Its efficacy has been well documented [15], [16], [17]. For
example, according to [15], the VAC obtained a 66% change in depth versus 20% for
"saline-wet-to-moist dressing". Because the VAC imposes (we'll talk about the VAC in
more detail shortly) negative pressures on the wound bed, it is a good model system in
which to explore the action of mechanical forces on the process of wound healing (the
VAC obtains impressive accelerations in the wound healing process).
However, the mode of action of MMF therapy devices is still not completely understood.
Let's look at some of the theories that have been put forth, and then we'll talk about our
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hypothesis-which says that micromechanical forces play a vital role in the VAC
sponge's mechanism of action in accelerating wound repair.
Many theories have been advanced to explain the physiologic basis for the marked
improvement in clinical outcomes achieved by the MMF device. One of these proposes
that the application of suction evacuates interstitial fluid and cellular debris and reduces
local edema, decreasing the likelihood of wound infection [18]. Although this may be an
important mechanism for a selected subset of wounds, we have observed many MMF
therapy-treated wounds in which minimal fluid was extracted; nevertheless, in these
wounds, dramatic healing responses were observed.
Also, it is proposed by many that the MMF device creates a hypobaric pressure which
then causes an increase in blood flow to the wound bed. These effects have been shown
to accelerate the formation of granulation tissue [19], [20], [21], [22]. It is interesting to
note that intermittently applied subatmospheric pressure has produced superior results,
possibly because of mitigating the cellular desensitization that occurs with exposure to
continuous subatmospheric pressure [18].
In addition, many have noticed increased granulation tissue, decreased bacterial levels,
and increased cell growth in MMF-treated wounds. Dr. Orgill and colleagues at the
Brigham and Women's Hospital have observed similar changes in their own patients.
However, we believe that the cause may be secondary to an underlying biologic effect.
Thus, although it is likely that all of the above factors play a role in the action of the
MMF device, we propose that the application of micromechanical forces to the wound
site may be the most significant mechanism of action.
For example, directional growth of capillary sprouts is also promoted by tension
application in three dimensional angiogenesis models in vitro [9]. Moreover, it is known
that endothelial cells in the vasculature express a different array of genes depending on
whether they were exposed to static, laminar, or turbulent flow [10], [11], [12]. It seems
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that cells are able to sense mechanical forces and respond through the regulation of
specific genes and the induction of cellular programs. The exact mechanisms for these
effects are not as yet completely understood but likely are related to conformational
changes in the cytoskeleton in response to mechanical forces. It is our hypothesize that
the application of mechanical force to wounds induces tissue deformation at the level of
individual cells, leading to cell stretch, thereby providing a powerful mechanism for
inducing cell proliferation and angiogenesis and hence promoting wound healing
At the Brigham and Womens Hospital, the MMF device has become the most common
treatment modality for complex wounds. The device consists of a porous open-cell
sponge (polyurethane or polyvinyl alcohol) applied to a wound and covered with an
occlusive dressing. The sponge has a tube connected to a vacuum pump which applies
subatmospheric pressure to the sponge (see Fig below). In a porcine wound model, the
MMF device was shown to increase blood supply and reduce the incidence of infection
[19]. The MMF device has been proven to be effective at treating both acute and chronic
wounds [20], [21], [16]. Thus, with the above background, we wanted to investigate other
possible mechanisms of action that may help explain how the MMF device works.
Let's quickly look at one example of the MMF device. A picture of the VAC system is
shown next [23]:
Another product from KCI is shown next [24]. This product "...combines VAC therapy
with Instillation therapy to assist in the irrigation and cleansing of wounds and the
removal of infectious materials" [24].
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The VAC works by imposing a negative pressure on the surface and margins of wounds.
The device applyies this pressure through a special dressing placed in the wound cavity
or over a flap or graft [24]. Currently, the therapy is indicated for "chronic open wounds,
diabetic ulcers, pressure ulcers, acute and traumatic wounds, flaps and grafts, dehisced
wounds, and partial thickness bums" [24].
Pressure
imposing
'pump'
Sponge-this is
'packed' into the
wound-this sponge
can be cut to size
A schematic of a MMF therapy device is shown next [2].
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Given that the MMF device works, we'd still like to know why it is important to study
the effects of forces on tissues with this particular therapeutic paradigm. What makes the
MMF therapy so pertinent is that it is one of the few effective therapies that can treat the
types of wounds described above (it is also quite suitable as an adjunct therapy, being
used to treat wounds in the acute time frame after which other therapies can take over)
[25]. The market for such wounds is large. Let's take a quick look at the market forces
driving this product.
MMF market analysis
According to [25] the total market for the VAC was estimated to be 1.4 million patients
in the US in 2004 with an approximate growth rate of 13%. KCI obtained revenues of
$992.6 million in 2004 and this is projected to rise to $1.5168 billion by 2006. Thus, the
VAC is an important therapy [25].
The VAC applied to human patients however forms the tail end of our analysis. To better
understand the effects of forces on wound healing, we need to start by decoupling the
effects of forces on wounds and the effects of forces on tissues. By studying in isolation
the effects of forces on tissues, we can then do the more detailed analysis taking wounds
into account.
16
The strains imposed by the MMF device are significant
Further, before we even start, we need to make sure that the wound does indeed see
forces and stresses that are strong enough to impact the tissue physiologically. However,
what defines physiologic strains in the wound (and by extension physiologic stresses)?
To answer this question, we looked at other wound and tissue systems where the strains
have more clearly been measured.
For example, Miyajima [13] has shown that osteoblasts seeded in vitro show maximal
growth at 17% strains, while Akhyari et al have shown [14] that a 20% strain (or stretch)
"enhanced the formation of a three-dimensional tissue-engineered cardiac graft by
improving the proliferation and distribution of seeded human heart cells and by
stimulation organized matrix formation resulting in an order of magnitude increase in the
mechanical strength of the graft."
We then developed a finite element model to study the strains in wounded tissue. We
found that the simulated tissue under MMF device conditions had strains that were
similar to those seen in different tissues under optimal conditions for growth [2]. This
study is described in detail further down in the thesis.
Decoupling force study from force study in wounds-gene expression study of rat
ear stretch
After validating that the strains set up in the wounded tissue exposed to the MMF device
are reasonably high enough to cause physiologic responses, we then designed an animal
model where we could study the effects of forces on tissue. Prior work done at our lab
has studied the rat ear because it is very thin and can be easily visualized under the light
microscope. This makes studying the vessels that drain it possible. We extended this
model for our tissue response to force study.
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Possibly the best way to characterize the response of a tissue to a stimulus is to look at
the changes that occur in the network of protein interactions that make up the cellular
machinery. However, current technology doesn't allow us to do this globally within the
cell. A next best way to characterize the tissue response is to study the gene expression
changes that occur with a stimulus. This is therefore what we did next. Later down in the
thesis, we will discuss the rat model that was developed as well as the gene expression
study that was conducted on the tissue obtained from this model.
Since both our models of analyzing forces (rat ear and human skin) both deal with skin,
we need to understand the structure of skin. We do this next. After this, we need to
understand the series of events that take place once skin is wounded. We discuss that
after we look at normal skin.
Brief review of the structure of skin (epidermis and dermis)
A cross section of the skin is given in the figure below. "The epidermis is a stratified
squamous epithelium that mainly serves as a protective barrier. The epidermis is about
0.1 mm thick, but on the palms and soles, the thickness can be greater (0.8-1.4 mm). The
keratinocyte is the principal cell of the epidermis and it serves to produce the protein
keratin" [26].
The thickness of the dermis can range from 0.6mm in the eyelids and 3mm or more on
the back, palms, and soles. The dermis can be divided into a thin upper layer, called the
papillary dermis, beneath the epidermis interdigitating with the epidermal rete ridges. The
papillary dermis is composed of loosely interwoven collagen. Deeper down is the
reticular dermis, composed of coarser and horizontally running bundles of collagen [26]
Collagen fibers constitute 70% of the dermis. They impart structural toughness and
strength. Elasticity in the skin comes from Elastin fibers that are arranged in all directions
in the dermis. Elastin is found more near the hair follicles and sweat glands (less in the
papillary dermis) [26]. The following figure is from [26].
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Here's another cross section of the skin [27].
w
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"The dermal ground substance consists of a semi-solid matrix of glycosaminoglycans
(GAG) which impart movement to some dermal structures. In addition, the dermis
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contains: fibroblasts which synthesize collagen, elastin, other connective tissue and GAG;
dermal dendrocytes which are dendritic cells with immune function; mast cells;
macrophages; and lymphocytes." [26]. The following is also from [26].
Wound repair-concepts and events
Now that we've talked about the normal cross section of the skin, we will talk next about
what happens during the process of wound repair. This will lay the background upon
which we will impose mechanical force effects.
There are 4 phases in wound repair: a) hemostatic phase in which blood loss is arrested,
b) inflammatory phase, in which inflammatory cells recruited to the wound site clear up
the debris and control infection, c) proliferative phase, in which granulation tissue and a
provisional matrix are laid down and reepithelialization occurs, and d) remodeling phase,
in which matrix is remodeled and wound is contracted [28].
In the hemostatic phase, the blood loss is arrested through the formation of a platelet plug
enmeshed in a network of insoluble fibrin molecules [29].
In the inflammatory phase, neutrophils and macrophages are the two cell types recruited.
Although neutrophils play largely a microbicidal role, wound healing is severly
diminished in the absence of macrophages, whose secretions include cytokines that
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attract and influence the next cell types involved in wound healing (fibroblasts,
endothelial cells, and epithelial cells).
The proliferative phase is the next phase. It only begins after inflammation subsides (a
chronic lesion occurs if inflammation doesn't subside). This phase is defined by the
formation of granulation tissue (which is loose connective tissue with a high level of
vascularization) [29], and epithelialization.
During this phase, the wound facing side of the basement membrane [29] is degraded by
the endothelial cells that migrate along fibronectin and other matrix components [30].
The new endothelial cell junctions are leaky. Macrophages recruit Fibroblasts which then
lay down the matrix framework of collagen III and I, gycosaminoglycans, and
proteoglycans [30].
Wound contraction, the final phase, occurs through either of two proposed mechanisms:
1) matrix remodeling and reorganization, and b) myofibroblast activity [29].
Rest of the thesis overview
We start out first, in the next chapter, by studying the different models of the effects of
forces on tissue and different models of wound healing. We then end by explaining why
it is we decided to use the three models that we used (finite element mathematical model,
rat ear model, VAC device on human model). The chapter after the next, we then
continue our study by exploring the forces seen in a simulated wounded tissue and the
scale of these forces. This will tell us if the forces are large enough to create any
meaningful effects. The surface strains are then determined to see if they are in the range
of strains seen in other tissue types.
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Chapter 2
Literature review: wound healing models, study of forces on tissues
models
Wound healing: models
Any given wound is a complex and unique occurrence whose state depends on the unique
circumstances that created it. In order to be better able to understand [31] and classify
different wounds (and also to pinpoint specific expression profiles in relation to isolated
stimuli and wound states), we need to look at different reproducible models that are
currently in use or have been used for wound healing.
Experimental models are also useful for evaluating safety and efficacy of therapies for
wound healing [31]. There are essentially three types of models (4 if we count
mathematical models). a) in vivo animal models [31], b) in vivo human models, c) in
vitro models [31] [32], d) mathematical models [2]. In vitro models can themselves be
divided into singlecell systems, multicellular systems, or organ cultures [31].
The animal models can further be classified under type of wound created. Thus, [32] talks
about (in turn): Excisional wound healing; reepithelialization; incisional wound healing
etc.
Many animal models exist to represent the state of healing of wounds in humans [33].
The validity of a model rests on its closeness in being able to represent this state
faithfully. Lindblast [33] says that "...we are not in need of models per se, but rather
models that more accurately reflect the biological processes occurring in humans during
normal wound healing." For example, if a model is representative of the wound healing
in humans, then the cells will go through a similar evolutionary process, secreting similar
growth factors and cytokines. Other metrics relating to the healing process will also tend
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to be similar. For example, the rate of wound closure should also be the same, as should
also be histologic and immunohistologic sequence of events. Other metrics include
optical-visual techniques, ultrasound, and computer imaging [34].
One model discussed in [34] uses pigs to represent human epidermal wound healing.
According to this paper, pigs and humans share many commonalities in their wound
healing process as well in the anatomy of their skin. The relative thicknesses of the
dermis and epidermis are similar in both; both have epidermal reteridges (which are the
intrusions between the dermal papillae-that are the ridgelike lines in the hand and foot;
in other words, the reteridges define the valleys between the protruding ridges on the
hands and feet). There are other similarities listed in [34]. The pig skin however differs
from the human skin in having an elastic membrane in the hypodermis (a layer of cells
below the epidermis).
This membrane therefore prevents any wound study from going beyond 28 days when the
wound is completely closed in the pig. The authors in [34] tried to circumvent this by
using a PTFE chamber that sought to arrest this wound closure through this mechanism.
(these authors also subjected the wound tissue to mechanical tests to evaluate the tensile
properties of the scar tissue formed).
Reproducibility in creating the wounds is a problem. For example, the authors in [32]
chapter 2 (methods in reepithelialization) talk of the difficulty in creating constant
thikness epithelial wounds.
The pig was not chosen as a model system because it is difficult to keep pigs because of
their size. Further, since we wanted to use Affymetrix chips in our analysis, we decided to
use a rat model. Affymetrix chips for Rattus Norwegicus are available. Further, previous
work at our lab has looked at effects of stretch on rat ears.
Murray [35] attempts to create mathematical models of epidermal and dermal wound
healing, saying that although wound healing is a complex process that is badly
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understood, only mathematical models can convert "an understanding of the underlying
mechanisms into a predictive science. Another attempt to model wound healing[35] is
performed by Sherratt. In keeping with this idea of using quantitative tools in modeling
wound tissue behavior, we used finite element analysis in obtaining strain and stress
profiles of simulated wound tissue.
Wound healing: mechanical effects
Cells are able to sense various types of stimuli, and, "...are known to orient and migrate
in response to gradients of light intensity, electrostatic potential, and gravitational
potential" [30]. Further, "...transient mechanical stimuli can induce motility of stationary
fish epidermal keratocytes" [30], and mechanical tension can induce sensory and brain
axons of chick neurons to be elongated [30]. Cell substrate rigidity also affects their
motility and their morphology [30]. "Directional cell movement can be promoted by
direct mechanical distortion of cells, for example, by pushing or applying fluid pressure
with a pipette [30].
Wound healing: mechanical models
An in-vitro model by Ingber et al in [30] showed that cells take on the shape of a micro-
islands over which they are placed. Further, in the presence of motility factors such as
PDGF cells extend their lamellipodia preferentially from the corners onto non-adhesive
areas outside the islands [30]. Cells contain motility receptors that are stimulated by
PDGF (platelet derived growth factor) ([30]-page 1199). These motility receptors do
not localize to corners when cells are grown on square islands [30]. However, vinculin
molecules do localize to the corners as do stress fibers of actin [30]. The following shows
pictorially what is stated in [30] page 1199.
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The paper concludes that there is "tension molding" of the actin network (page 1202)
because the cell is distorted into a square shape. This causes lamellipodia to be focused at
the corners (9). "The novel finding here is that this targeting of isometric tension to the
corners of square cells somehow creates a localized microcompartment in which
formation of lamellipodia, filopodia, and microspikes is promoted in the absence of a
gradient of soluble chemoattractants." [30].
Wang [36] tested whether integrins connect directly to the cytoskeletal framework in
cells or whether the integrins connect to the outside membrane which then connects to the
network within cells. To test this, a strain was applied to the integrin receptor. If this
strain was supported by the cytoskeletal network directly, then the disruption of the
network would release the force of resistance to strain on the receptor. Thus, when
cytochalasin was input into the system, there was an increase in angular strain verifying
that the integrin receptor is coupled to the cytoskeletal network directly (although why
the author mentions "for only 15 minutes" on page 1125 isn't clear to me). Wakatsuki
[37] has shown that cytochalasin D affects the mechanical properties of cells
(cytochalasin, disrupts the cytoskeletal network in cells).
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Dembo [38] shows that the traction forces used to move fibroblasts forward are applied
by the lamellipodia [at the focal adhesions], while the rest of the cell body is passively
pulled forward. Traction is also studied by Wang [39] who shows that if cells take on the
shape of a square island, the traction is highest at edges.
Waters et al [40], state that mechanical forces involved in ventilator-induced lung injury
may cause an elevation of proinflammatory cytokines, and that "microarray analysis of
human lung epithelial cells demonstrated that cyclic mechanical stretch alone profoundly
affects gene expression.
Mechanical forces gene expression (in fibroblasts and other cells)
The extracellular matrix distributes mechanical forces applied to it to adhesive structures
in the cell (including integrins) [41]. These forces then are transduced into intracell
signals that rearrange cytoskeletal proteins and cause the expression of cytoskeletal genes
such as alpha-skeletal, alpha-smooth muscle actins, filamin A, talin, and vinculin.
"Filamins are actin-binding proteins that organize actin filaments into orthogonal
networks and enhance the rigidity of the actin cytoskeleton." [41]. Thus the force that is
applied to the cell causes the cell to essentially become more stiff thereby resisting the
deforming effects of the externally applied force. This paper [41] says that forces cause
disruption of the microtubule structure in the cells leading to increased filamin A which
causes an increase in actin levels thus causing increased rigidity. Compounds that also
disrupt the microtubule assembly also lead to increased actin through the increase in
filamin transcription (if the microtubule is stabilized, the actin assembly is not affected).
Chiquet et al [42] have shown that tenascin-C (an ECM component) is directly regulated
by mechanical stress. "Fibroblasts sense force-induced deformations (strains) in their
ECM," and forces cause the fibroblasts to increase the induction of the mRNA of
tanascin-C directly without the release of other factors into the medium [42]. The
fibroblasts need to be pre-stressed in order to be able to induce tenascin-C in response to
an external force. If they are not pre-stressed, they don't respond to forces with the
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transcription of tenascin-C. The "integrins within cell-matrix adhesions can act as strain
gauges, triggering MAPK and NF-B pathways in response to changes in mechanical
stress" [42].
Kraiss et al report that fluid flow through the application of shear stress can
independently activate pp70Ws6k, which is a key intracell "checkpoint in the transduction
of mitogenic and other extracell signals [43]. This paper also shows that the response that
they observed (the activation of pp70Ws6k with fluid shear) was cell type dependent.
Thus they didn't see this same response in CHO cells, or Swiss 3T3 fibroblasts [43].
Although the effects of different cell types to forces as we saw in ref [43] are cell type
dependent, the principal argument is that forces can affect the transcriptional/translational
paradigms in cells.
Chien et al show the effects of mechanical forces on signal transduction and gene
expression in endothelial cells [44]. This paper says that shear stress is dependent on
blood flow and vascular geometry, and strain is dependent on transmural pressure, the
mechanical properties of the vessel. It would perhaps be more appropriate to specify that
the boundary conditions impose a shear stress causing that variable to become
independent and then making the strain the dependent variable (Stress and strain are
coupled). The ideas in this paper are encapsulated in the following relation:
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Another paper dealing with shear stresses is by Ji [45]. Low shear is suspected of being
implicated in atherogenesis (low shear is found at bifurcations where the flow is
characterized by vortex flows). Steroids which act at the glucocorticoid receptor are
known to reduce inflammation. This paper reports that shear stresses cause activation of
the glucocorticoid receptor, thus establishing the link more concretely between shear and
the lower atherosclerosis seen at regions of the vasculature with comparatively higher
shear stresses [45].
Because prior work at the Orgill lab has studied that rat extensively and because rat (or
Rattus Norvegicus) Affymetrix chips are available, and also because rats are far easier to
keep and maintain than larger animals such as pigs, we decided for the animal in vivo
study to use rats in our study.
Further, the force input was applied to the rat ears mainly because the Orgill lab has had
extensive experience applying forces to the rat ear. One of the reasons the rat ear has
been chosen is that changes in the rat ear vasculature can be looked at directly under a
light microscope (since the rat ear is thin enough to facilitate this).
The mathematical model we used in our wound study to study the mechanical effects used
finite element analysis as the implementation tool.
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First, we study the strains that are obtained in a skin wound model applying finite
elements. This study will give us insights into a mechanism of the VAC device that we feel
is significant in its efficacy-namely the effects of micromechanical forces in obtaining
enhanced outcomes. That the VAC obtains improved outcomes is not in doubt. Thus we
have a system that is highly mechanical in its effect on the skin (or at least seems so on
first inspection) and therefore is a good candidate to study the effects offorces on tissues.
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Chapter 3
Vacuum-Assisted Closure: Microdeformations of Wounds and Cell
Proliferation
As mentioned in the introduction, we wanted to test whether the strains obtained through
the application of the VAC are significant enough. Thus, we created a finite element
model of skin. A solid elastic linear, isotropic, homogenous model was constructed (thus
there were no empty spaces in the model) and fluid flow through this model was not
taken into account. The gage pressure to which this model of skin was exposed was set at
1 10mmHg (this was kept constant for all the analyses except the analyses where the
pressure itself was varied).
A finite element model was constructed. Further down we'll explain the specifics of the
model. The figure below shows that a mismatch between the compliance/elasticity of the
VAC sponge material and the tissue causes the tissue to intrude into the spacing between
the struts.
P1 (atmospheric pressure)
Occlusive dressing
P2 Sponge strut
Finite element model of wound bed
We have also compared the microdeformations of the wound bed to our finite element
model. As seen in the figure below, we find that our finite element model of VAC
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application to a wound bed predicting its microdeformations are comparable to histologic
evidence of wound tissue microdeformation in clinical wounds treated with the VAC
(see Fig below). This lends at least a somewhat qualitative validity to the finite element
model.
The use of finite elements in plastic surgery applications is well established. It is used in
applications ranging from the analysis of craniofacial stress, [46], to bum heat transfer,
[47] to skin deformation [48].
The wound was simulated using mechanical properties from the literature and assuming
that these properties were constant in all directions (in other words we assumed the
wound bed to be isotropic). By altering the distance between struts and the thickness of
the struts, we changed the physical properties of the sponge referred to as pore diameter
and pore volume fraction. We further demonstrate how the finite element analysis model
can be used to optimize the set of conditions that define the VAC system.
MATERIALS AND METHODS
Histologic Processing
Background histologic work to obtain tissue microdeformations was performed by
colleagues at the Orgill lab.
Routine biopsy specimens of five clinical wounds treated with the VAC for 4 to 7 days
were stored in formalin, embedded in paraffin, sectioned in 5pm sections perpendicular
to the wound surface, and stained with hematoxylin and eosin. Biopsy sections were
evaluated for surface undulations and cellular and vascular structures.
Finite Element Modeling
ADINA Version 8.0 (Adina R&D, Watertown, Mass.), finite element software, was used
to formulate the finite element analysis simulations in this study. The validity of these
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analyses was checked by the solution of closed form analytic equations. An order of
magnitude estimation is included in Appendix (put appendix number here).
The VAC Computational Model
The VAC device consists of a highly porous polyurethane sponge with spatial
connections between the pores, allowing subatmospheric pressure applied to the sponge
to be distributed equally throughout the sponge. The VAC device used today applies a
70- to 150-mmHg vacuum. The VAC is modeled as a series of pores with the
polyurethane sponge in contact with the wound. We assume the pores to be symmetric
and that there is no lateral displacement in the center of the pore. Furthermore, where the
wound contacts the sponge, we expect no vertical displacement. These boundary
conditions and pressure are applied in a two-dimensional finite element model. The
wound is modeled as a linear, homogeneous, isotropic, elastic material. Although a
nonlinear stress-strain relationship exists for the skin and other connective tissues, the
skin shows a fairly linear stress-strain curve in the observed strain ranges [49].
Furthermore, we varied the compressibility of the material (Poisson's ratio) to study this
effect on wounds. Five parameters were studied: stiffness of the wound (Young's
modulus of elasticity); compressibility of the wound (Poisson's ratio); pore diameter of
the sponge, defined by the distance between two struts in the model; pore volume fraction
of the sponge; and pressure applied to the sponge (or differential thereof). We modeled
variation in each of the above parameters. The figure and Table below are from [2]. As
each parameter was sequentially varied, all other parameters were assigned "standard"
values usually observed in the application of the VAC. See Table below (from [2]).
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Table: Finite element parameters studied
E (elastic modulus, L N P V
kPa) (pore diameter, mm) (Poisson's ratio) (pressure, mmHg) (pore volume fraction)
50
Varying E 70 1.2 0.49 110 0.889
100
0.8 0.842
Varying L 70 1.2 0.49 110 0.889
1.6 0.914
0.38
Varying N 70 1.2 0.43 110 0.889
0.49
70
Varying P 70 1.2 0.49 110 0.889
150
0.889
Varying Vf* 70 1.2 0.49 110 0.842
1_ 1_ 1 110.762
* Changes to Vf use strut sizes of 0.15, 0.3, and 0.5mm; 0.15mm is used when strut
thickness is not varied.
Simulation Parameters
Constraint boundary conditions. The system is modeled as a large number of pores with
associated struts such that the centerlines underneath the struts impose a symmetric
boundary condition. At the centerline underneath each strut, we assume no lateral
displacement. Vertical displacement will be slight because of the almost incompressible
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condition imposed on Poisson's ratio. This symmetric boundary condition was modeled
using half the strut thickness in the analyses.
Force boundary conditions. In this static case, no shear stresses are imposed on the wall;
therefore, all the forces act perpendicular to the wall. Thus, we impose only a uniform
pressure boundary condition in our analysis.
RESULTS
VAC Device Increases the Microscopic Surface Area of the Wound
Histologic sections of wounds were studied comparing areas treated with a VAC for 4 to
7 days to other areas in the same wounds not in contact with the VAC sponge. VAC-
treated wounds show a marked increase in undulating contour with protrusions and
indentations corresponding to the geometry of the sponge's contact with the wound (see
Figure below-from [2]).
Areas underneath an occlusive dressing only, without sponge contact, do not undulate
(see Figure below-from [2]).
34
El!ft _ I L
The following figure shows how areas under the VAC applied suction with the sponge
show microundulations (from [2]).
These induced surface irregularities cause an increase in microscopic surface area, and
thus local mechanical distention of tissue, without increasing the actual size of the
wound. Measurements of the surface length of a histologic cross-section of a wound
demonstrate an increase in surface length of 22 percent over 4 days compared with
wounds not treated with the sponge. In addition, a rich vascular network was noted to be
present in the wounds treated with the VAC sponge compared with control sites (Figure
shown above).
Finite element analysis of the wound-VAC system was conducted to directly predict the
strain imposed by the VAC sponge on wound tissue. Visible in the finite element
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analysis is tissue stiffness (characterized by Young's modulus), tissue compressibility
(characterized by Poisson's ratio), sponge pore diameter, pore volume fraction, and
variability of wound tissue strain over a range of imposed pressure (Fig.
A above). Higher strains can be induced by increasing pressure, increasing pore diameter,
or decreasing strut thickness. Strains are also predicted to be greater when mechanical
properties of the wound such as the Young's modulus or Poisson's ratio are decreased.
Using physiologic values for tissue, [49], [50], typical sponge pore diameter, and
pressures used clinically results in a striking resemblance between the finite element
analysis output and the histologic cross-section (Figure shown below-from [2]).
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Strain
Point-wise strain along the simulated wound surface was maximal in the regions close to
the struts and, consistent with a model of a thin membrane acted on by a uniform
pressure, nearly constant across the majority of the wound tissue.
Strain Variability along the Wound Surface
Surface strain varies in a repeating pattern across the wound tissue. Strain is negative
(compression) immediately underneath the sponge struts, as they indent the surface of the
wound. At an applied pressure of 15 kPa (110 mmHg) typical of the VAC, the tissue
quickly reaches a peak strain of 125 percent immediately adjacent to the struts (0. 15
mm), as the forces of strut compression and vacuum suction oppose each other
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maximally and most directly at the edges of the sponge pores. The bulk of the wound
tissue within the sponge pore, however, experiences lower strains (5 to 20 percent), with
tissue at the center of the sponge pore experiencing the lowest strains (up to 5 percent)
(see Fig below). These strains are dependent on wound thickness. At a wound thickness
of 1 mm, the center strains were 0.67 percent, whereas for the most superficial wounds
(0.5 mm), the center strains were 5.1 percent. The figure below is from [2].
110
8o
C
20
40 12 31 50 69 88 100
dbtanca along surfaCe
(%of por se)
Wound Healing Affects Tissue Strain
During wound healing, tissue elasticity and compressibility change, [49] and wound
displacements induced by the VAC, even at constant pressures, are likely highly time-
dependent. As wounds heal, they tend to become fibrotic with increasing stiffness
(Young's modulus of elasticity), thereby decreasing average wound strain. For example,
increasing the stiffness from 50 kPa to 70 kPa would lower the average wound surface
strain from 35 percent to 12 percent, with a concomitant decrease in peak strains from
200 percent to 125 percent (see figure below-from [2]).
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As tissue becomes fibrotic or edematous, the Poisson's ratio may increase, further
decreasing the average and peak surface strains. In the simulation, raising Poisson's ratio
from 0.36 to 0.50 (incompressible tissue) resulted in the decrease of average surface
strains from 26 percent to 22 percent (Figure B above). In the ranges studied, surface
strains also appear to be far more sensitive to changes in tissue stiffness than tissue
compressibility. Our model shows that raising tissue stiffness by 40 percent causes a
nearly 66 percent decrease in the surface strain, whereas an equivalent change in
compressibility results in only a 15 percent decrease. This suggests that changes in the
stiffness of the wound over time may be an important factor to consider when optimizing
therapies for healing wounds.
Applied Strains Are Device-Dependent
It has been suggested that cells can be induced to respond to growth factors and
proliferate when undergoing an optimal degree of strain [7], [51], [5], [52]. To examine
how changes in VAC device properties can be harnessed to produce optimal wound
tissue strain, finite element analysis models of the VAC were constructed with varying
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pore diameter, strut thicknesses, and imposed pressures. Strain is very sensitive to
changes in pressure. Doubling applied pressure from 10 kPa to 20 kPa also doubles
average surface strain (Fig. C, above), but doubling average pore diameter from 0.8 mm
to 1.6 mm results in only a 50 percent increase in surface strain (Figure C, center). In
addition, decreasing the thickness of the sponge struts causes a decrease in the average
surface strain (figure below-from [2]). Considered together, these results suggest an
exquisite sensitivity of the imposed strain to VAC device properties and demonstrate a
broad dynamic range of achievable strains in the wound tissue achieved by varying
device parameters.
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Conclusions from this study
We've already discussed in the introduction to the thesis the basis for our hypothesis that
micromechanical forces are at play in the mechanism of action of the VAC device.
We've shown that the strains obtained through the use of the finite element model do
indeed approach physiologically meaningful values. Let's now discuss how the VAC
device may be enhanced. We will then discuss some of the limitations of our model.
Enhancing the VAC Device
The finite element analysis results obtained here, particularly with respect to pore
diameter and strut thickness, may be helpful in optimizing VAC device design. For
instance, if higher strains are desired to facilitate cell proliferation, our data might suggest
that both increasing the pore diameter and decreasing the strut thickness will increase
overall average wound strains. Unfortunately, the model also implies that the higher
average strains thus achieved will inevitably be associated with tremendous
spikes in strains and stresses in regions immediatelyadjacent to the struts, which may
cause local damage to the wound.
Moreover, larger pore diameters may also simultaneously result in larger areas with
locally suboptimal strains. Indeed, our model suggests strains peak immediately adjacent
to the strut, become optimal (-10 percent) farther away from the strut, and become
suboptimal (<5 percent) with increasing distance. Optimizing sponge pore design thus
becomes a delicate balance between minimizing the central suboptimal strain regions and
minimizing high local strains caused by increasing the number of struts. Our finite
element analysis results imply that some of these issues might be addressed through the
use of stress concentration-reducing rounding of struts. A great deal of work in the
biomechanics literature correlates changes in elastic modulus and Poisson's ratio with
changes in tissue abnormality and injury, tissue type, and age-related modifications [49].
By combining these data with the kind of systematic analysis presented in this article, our
model could be extended to different tissue types or even to the same tissue as it changes
over time.
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If the VAC device does work as we have postulated, then it may be possible to effect
faster and more effective responses to wound healing by inputting forces directly to the
wound bed. First let's try to understand how forces may be transmitted through the
wound bed. The section 'A conceptualization of force-transmission to cells in the wound
bed' in the first chapter shows a schematic which explains that it is not enough to simply
apply forces from the outside on to the wound bed. Since the wound bed is essentially
composed of weak connectivities, any forces that we apply will tend to be dislocated
through only the stronger sections of the wound bed and the weaker sections will see
essentially no forces or strains (the stresses will rise-since now we have the same forces
acting on a smaller area-the larger global area because part of its links were severed-
will reduce to a smaller effective area). Thus, we will have done essentially what we said
above we should not do. We will have raised the principal stresses at the force carrying
loci while reducing to zero forces at the severed loci.
This is in essence why we need to input Micromechanical forces, or forces that act at a
local part of the wound bed at each part of the wound bed. By providing a scaffold that
will essentially create a stronger bed over which the cells can then attach themselves to,
we have created a stronger cross-sectional area, all of which can support the forces
applied.
Some other factors that can help to design a better scaffold for the Vac Assisted Closure
therapy include ascertaining whether constant strain is better (by fixing the applied
strain-a fixed strain needs to be able to control the force at each micro-loci by inputting
a fixed motion at each micro-loci regardless of resistance from the tissue), or is constant
stress better (ie by applying a fixed force). For example, in a healing wound bed, the
elastic properties of the tissue at each loci will not be the same. In other words, the tissue
will display non-homogeneous behavior in terms of material properties.
Further when a force is input, the force has to lower than the yield stress of the weakest
area of the wound bed. Otherwise the force will cause that area to expand until it breaks,
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and that will stop any further force transmission through that axis. One idea is to use
magnetic beads in a meshwork that can be moved through the application of an applied
field. This method however may suffer from the same problems that we see with constant
force application. If the density of beads is constant throughout the wound bed, then the
beads will see the same magnetic force and therefore we again end up with a constant
force boundary condition. However, if the density of the beads can be coupled to the
material properties of the wound bed, then we can couple the force to the wound bed
properties.
One way to do this may be to look for correlations between mechanical properties and the
physical condition of the wound. For example, in regions where the wound bed is
weaker, we may see more fluid material. Magnetic beads that don't disperse as well in a
more fluidic phase may provide a solution (although this is just an example-I doubt if
such particular beads exist).
Another (simpler) technique is to use a material that expands with temperature or with
some other input (such as a voltage-a piezo-electric material for example).
In both of the above uses, we would need to be able to separate the material from the
species (such as cells) in the wound bed that can couple to the material. This can be
accomplished by using connecting ligands on the material that can bind cells, but that can
be cleaved from the material (but not from the cells). Thus, once the piezo electric
material has fulfilled its task of force application, it can then be removed from the wound
bed.
It would seem reasonable to assume that if the forces are applied uni-directionally with
time, then the collagen fibers and other structural components will align along the applied
forces. This usually is the reason for the strong retractive forces seen in scar tissue.
Anisotropy (ie directional nature of the mechanical properties of a material) is thought to
confer structural strength in the case of myocardial tissue. Further "protein turnover and
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myofibrillar structure are regulated differently by stretches applied parallel or
perpendicular to the long asis of aligned cardial myocytes".. ."suggest[ing] that both
cellular prealignment and biaxial stretch protocols will be required to optimize directed
growth and remodeling of evolving engineered heart tissues [53].
Limitations of the Model
Although biologic tissue is a nonlinear viscoelastic system, 15 our model was constructed
as a linear elastic system. The linear assumption was deemed reasonable, as the tissue
stress-strain relationship remained linear over the relatively small range of strains on
most elements. Destruction of tissue architecture was assumed to render the normally
anisotropic material properties of healthy tissue close to isotropic in the wounded tissue.
Furthermore, the biologic system is dynamic, and local cell growth partially relieves
stresses that occur in wounds. These aspects of the wound-healing process were not
studied in our model. We assumed the struts in this model to be fixed in space and
completely incompressible. However, as the actual struts likely have a degree of
compressibility, the model may overestimate the peak strain spikes near the struts of the
VAC device.
Extension of this work to gene-expression study
Now that we've seen that the strains obtained in a wounded model of the skin are
significant, we next study the gene-expression profile changes that may occur in a study
that studies the effects of forces on normal tissue alone. A future extension of this work
will look at the effects of forces (in the context of the VAC device for example) on
wounded tissue. Such samples are in the process of being generated.
The next chapter thus is a study of the gene-expression profile changes seen with the
application of forces to rat ears.
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Chapter 4
Effects of forces (stretch forces) on the gene expression profiles
of rat ears
With the analysis in the previous chapter showing us that significant forces are imparted
to a tissue subjected to the VAC device and with the additional evidence that the VAC
device does show substantial improvements in wound outcome, we next study at the gene
expression level what types of genes (and therefore by extension their products, proteins)
are differentially expressed in a tissue subjected to a force.
As explained in chapter two, we decided to use the rat ear in our exploration of the effects
of forces on normal tissue. An extension of this thesis will look at the effects of forces on
wounded tissue (rat ear in our experiment, even though it is stretched with non-
physiologic forces is assumed not to be wounded because we have not induced any
external tear on the ear).
Prior work done at Dr. Orgill's lab by others has shown that rat ears exposed to forces
show a growth in the number and size of the vasculature draining the ear.
With the above work accomplished, we would now like to explore this mechanism at the
genetic level by decoupling it from the way the VAC obtains the strains. In other words,
we would now like to apply mechanical forces directly to tissue to see what effect this
has on the tissue. A gene expression analysis on a suitably excised ear tissue from each
model is then be conducted to look for patterns of gene expression.
Work done by Dr. Orgill and co-workers has shown that a rat ear exposed to a constant
strain becomes more angiogenic-with the vasculature showing significant growth both
in size and density following the application of a strain or force. An intermittent
application of force has been shown to show even better outcomes with the VAC device.
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It is also known that cyclic tension increases the rate of breast tissue growth. Thus an
extension of the constant force work is now being studied by Dr. Orgill and Co-workers
to see whether a varying force gives superior or different results. To start with, however,
in our gene expression study, we will study only the effects of constantforces.
A validation of this work can be carried out by essentially 'knocking out' the gene or
geneset (we'll discuss genesets further down) that seems to show promise through our
analyses.
Importance of studying gene expression
The goal of gene expression studies is to find a set of genes that show differential
expression with respect to the experimental conditions. Genes that are differentially
expressed and whose expression level changes are correlated are believed to be part of
the same biological pathway. Thus gene expression profiling can give us an
understanding of the pathways underlying the process being studied.
Analyses (typically) used to study gene expression
One popular technique for obtaining important genes relevant to a system is hierarchical
clustering. This technique is especially powerful when applied to a system that is clean
and simple (for example free of too much noise and where expression level changes are
not so subtle). One metric used in hierarchical clustering is the Pearson Correlation
coefficient. However, when the system being studied is 'messy' then hierarchical
clustering can give us results that may be misleading.
If for example, the results of an expression study give us a high fold changes in a set of
genes, then these genes will quickly stand out from the noise (figure on left) and
expression changes will speak about similarity between genes (noise is given by the
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arrows). We will then conclude (for example) that genes 1 and 45 are closer in expression
changes.
Time
point 2
Time
point 1
TX
TI
T
TX
II II
TX
X
T
X
X
TI
TX
Gene 1 Gene 45
(say)
Gene 88
(say) Gene 1 
Gene 45
(say)
Other analyses that are used to obtain important genes and gene clusters (or sets) are self-
organizing maps, principal components analysis etc.
These types of analyses are not useful in our dataset
If, however, as we see in the figure on the right, the expression changes are subtle, then
depending on where in the value spectrum given by the noise the data point lies, we may
end up saying that gene 1 correlates more with gene 88 (say) and not with the gene that it
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Gene 88
(say)
is really correlated with (gene 45) if there is no noise. Thus, we need a different way of
extracting important genes and gene clusters.
Because many gene sets and pathways have over time been extracted from many simple
and clean experimental systems, we can test different gene sets and see which ones seem
to be the most strongly 'enriched' in our system. This is where GSEA or gene set
enrichment analysis enters the picture.
Hierarchical clustering cannot be used in ranking the genes in GSEA
We rank the genes in terms of two data points (or sets) by taking the difference between
the two points in expression values. This gives us a range of absolute differences.
However, hierarchical clustering will only look for closeness in expression between two
points. Thus two points which are closer in expression space will be placed 'highest'. As
we've discussed above, if the noise masks subtle expression differences, the wrong genes
will end up being correlated. Thus, a simple difference in expression levels (or in our
case, the 'difference paired t statistic squared') will give us a ranking that is not
'influenced' by noise effects.
Time 1 Time 2
Gene1
Gene2
Gene3
Gene4
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Now if we rank the genes according to difference, we'll get Gene3 > Gene4 > Gene 1 >
GeneG. However, if we cluster hierarchically by correlation, genes 4 and 1 will be placed
together at the top since their expression levels patterns are the most closely aligned.
Time series analysis of rat ear stretch
To keep a continuous thread to our story, I will begin at the beginning, where I applied
stretch to rat ears and then expression profiled the ears. It may help to keep in mind that
we are trying to understand the effects of forces applied to rat ears on the gene expression
changes that occur in the rat ears. Here's an overall summary of the scheme:
1) Apply stretch to rat ears
2) Excise the ears and immediately freeze them in liquid nitrogen at different time points
3) Store the frozen ears at -80C
4) Extract RNA from the ears
5) Hybridize this RNA to affymetrix RAT chips 230 2.0
6) Obtain expression data
7) Conduct GSEA on the expression data
8) Find groups of highest enriched genesets (or rather probesets) that also have a low P
value (computed with the permutation testing)
9) Check which genes correspond to the probesets in each geneset
10) Look for a biological mechanism that may help to lend support to the enriched
geneset
A final follow up of the above may be to conduct further biological validation steps to
test the biological significance (if any) of the results.
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The rat ear stretching experiment
The rat ear was chosen to study the effects of forces on tissues because it is relatively thin
(and therefore easily visualized under the microscope). It is also easy to apply forces to
the ear. Further most of the ear is skin (with a thin internal lining of cartilage). The rat ear
is also fairly large (compared say to a mouse ear) and therefore it is easier to handle (pigs
are bigger but they are far more expensive and cumbersome to maintain).
Also, previous work at the lab had been conducted on the rat ear to study the effects of
forces on the size and number of blood vessels in the ear. Thus, there was a pre-existing
model that could be further modified to perform our study.
The ear gluing and stretching system
For this experiment, it was important to have a system that could apply a stretch force on
the rat ear without explicitly wounding the ear. This is because, as mentioned earlier, we
are trying to decouple the gene expression profile under forces from the gene expression
profile under forces on a wounded tissue. This way, we obtain an understanding of the
effects of forces independently of tissue wound.
Thus, we could not suture the ear to any force producing mechanism, because the suture
would create an inflammatory response that could potentially overwhelm any other
response. A mechanism that had been worked out in Dr. Orgill's lab used latex taken
from a lab glove to glue the rat ear to an externally tethered mount. Superglue was used
in that technique to bind the ear to the latex piece. However, we needed to keep the ears
glued for an extended period of time and so we had to search for other methods that could
give us longer lasting binding. Superglue is ethyl cyanoacrylate. However dermbond is
Octyl-cyanoacrylate and its application gave us far longer gluing properties. The
stretching system is described next.
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One solution to the ear gluing problem
When items are glued together, they have to resist two types of forces: shear forces and
perpendicular forces (forces that tend to pull the two pieces apart in tension). By using a
surface with a high friction coefficient, we can add to shear resistance of the glue, since
frictional forces will aid in the strength of the glue in shear. It needs to be remembered
that glue acts through bonding interactions and not just Wan Der Waals/close
electrostatic interactions while friction acts through the latter. One idea to increase a
glue's holding strength is to use a clamp around the piece (say ear) to be glued to with a
material (say two pieces of latex). If the clamp is rigid, then the normal forces acting on
the latex pulling it off the ear go almost to zero, thus leaving shear forces as the sole
forces holding the ear to the latex.
Further, if the clamp is slightly pushed inward, frictional forces are increased highly since
friction depends on the normal force with which the surfaces contact.
This system however was not used in our study. For one, we were able to obtain
dermabond which by itself held the rat ear in place with the latex for long enough periods
of time. Further, some of the rat ears showed tearing. This could have been because the
clamping forces applied were too strong. This technique however held even with the
weaker superglue (without use of the dermabond) even when the ears were partially or
completely torn off.
The stretching experiment
Male Wistar Rats (scientific name Norvegicus Ratticus) were used in all our analyses
(mixing males and females would have entailed possible impracticalities with
pregnancies). The rats were ordered at 150g each. We decided to study the effects of
forces at 10 discrete time points. Because earlier time points were probably more
important in the response to mechanical stress, 7 of our time points were taken in the first
24 hours post stretch. Three rats were used for each time point. One ear of each rat
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(chosen randomly) was stretched and the other ear was left unstretched (this became our
control).
The overall stretch apparatus is shown below and the scheme for obtaining stretch is
shown two figures down.
Plastic caps from were obtained. The rat ear is shown in better detail on the right side of
the figure. The rats were allowed to acclimatize at least overnight to their new
surroundings.
In preparation for the stretch apparatus application, the rats were anesthetized with
ketamine and xylazine (for an approximately 200g rat, use 0.2ml Ketamine and 0.15ml
Xylazine). The anesthesia was injected into the lower abdomen. The angle of the syringe
was kept at a low angle so that the anesthesia was placed into the peritoneum (but not so
small as to be constrained in the overlying musculature-anesthesia flows faster out of
the peritoneum than it will from overlying muscles) in the lower abdomen right above the
bladder region of the rats.
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During the procedure in which the apparatus was applied, the rats were given
maintenance doses of ketamine (maintenance doses of ketamine-0.06ml-are given
every 2 hours or as needed if the rats seem to be waking up).
Once the rats were anesthetized, their lower backs were shaved with a mechanical hair
trimmer. At this location, a number identifying the rat was written with a marker pen.
Then, a depilatory was applied to the ears and left on for 4 minutes after which it was
wiped off first with dry paper napkins and then with ethanol.
Separately Latex gloves (specific company) were washed with soap (to remove any
powder that may have been present on them) and then cut in strips that were 5mm wide
and 14mm long (check on this). The strips were left to dry. Usually latex gloves are
coarser on the outside (the side used to grip objects). Glue was used on this side to attach
the strip to the ear.
Dermabond (Octyl cyanoacrylate)-which sets very fast (in a matter of minutes) was
used to glue the strips to the ear. Each strip was applied at three points on the rat ear as
far spaced as possible. Each strip was folded such that half bonded to the front side of the
ear and the other half when folded bonded to the back side of the ear (as shown in the
figure above-it almost looks as if there are two strips per point but that is shown only
for clarity purposes.
A little bit of space was left between the folded parts of the strips (in other words out of
the 14mm, only about 5 or 6 mm actually contacted each side of the ear). About 2mm
was left away from the ear. To this 'jutting' part, we connected a suitably calibrated
rubber band using sutures. The rubber band was calibrated using a tensiometer such that
50g of force was applied to the ears.
A plastic bottle cover was obtained (put down name of the bottle brand here). Three holes
were drilled into the cover as shown below.
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Once we've attached the latex to the rubber band through sutures, we pass the rubber
band through its corresponding hole in the plastic cover and then measure the amount of
stretch the rubber band obtains equal to that needed to give us a force of 50g (the rubber
band is calibrated by marking 1mm marks on its unstretched length and then stretching it
until the tensiometer shows 50g-this stretched length is then measured-this is the
length that the rubber band is then later stretched to give us the requisite 50g force).
After measuring the stretch in the rubber band we then clamp the rubber band at that
stretch by using a titanium clamp (we also devised our own clamp by using staples-we
extracted free staples and cut them in half, and then used each staple within a titanium
clamp 'applier' to clamp the rubber band-the clamp 'applier' is essentially a scissor like
implement that can 'squeeze' the half staple onto an object as shown conceptually
below).
Three rats were used per time point (giving us three biological replicates). One ear was
stretched, the other ear had exactly the same mechanism applied except that stretch was
not applied. This ear (chosen randomly) formed the control ear.
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Once the stretch mechanism had been applied, an elizebethan collar was placed around
the neck of the rats to prevent them from accessing the mechanism with their forelimbs.
We kept only one rat per cage as we found that if we kept two to a cage, the rats 'helped'
each other remove the collars!
After the collars had been placed around the rat necks, we sutured the plastic covers from
each ear to the collar gently. This kept the ears spread outward slightly and prevented the
rats from dragging their ears on the material in their cages.
The rats were given buprenorphine (0.03mg/ml) to relieve their pain from the stretch.
The rats were then returned to their cages. Buprenorphine was administered twice daily
for 4hours (for those rats that were used for longer time points) after which it was
stopped.
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Approximately 30 minutes before the time to sample the rat ears (which essentially meant
that the rat ears were excised with a surgical scalpel), the rats were anesthetized (it was
necessary not to euthanize the rats before excision as this could affect the gene expression
profiles that would be obtained from their ear tissue.
Liquid nitrogen was obtained and using a pair of tweezers, the excised rat ear was
directly inserted into the liquid (it is important not to bring any part of the body in direct
contact with the liquid as this will damage the area-especially if the contact is
prolonged). The frozen ear was then stored in an eppendorf that was suitably marked and
the eppendorfs were then stored at -80C until they were ready to be taken to the RNA
extraction and hybridization facility. All samples were kept in dry ice after they were
frozen and when they were not in the -80C freezer.
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Gene set enrichment analysis
In their paper [54], Mootha et al use GSEA to find gene sets that are important in
diabetics. They didn't perform a time series analysis. If they had performed a time series
analysis, they would have had (say) a set of time points of diabetics over normal controls.
Thus, our data is really analyzable in two days. We can perform an analysis that performs
GSEA analysis over all time points comparing stretch with controls. This analysis would
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test whether given that a gene set may be important in our system, whether there is in fact
a difference between control and stretch conditions.
If, however, we normalize the data between stretch and control by taking their ratios, an
SVD then on the data matrix may give us insights into the genes that may be important
over the time course of the experiment.
We can think of two types of genes (or gene sets-we'll define this later) that may be
affected (albeit they could turn out to be the same) between control and stretch conditions
and those that may be affected over time. So let's say that the effects of stretch are time
independent. For example, if gene A is upregulated between control and stretch but stays
at the same level of upregulation over time, then if we normalize between control and
stretch for each time point, the ratio of stretch to control for gene A will stay constant,
and gene A will not pop out of any analysis of variance. However, if the ratio shows a
shift over time, then an analysis of variance will pop out this gene.
Mootha as we explained above had eight replicates at the same time point. Thus they
could average their control and stretch conditions and take the differences to rank their
genes. However, we cannot do this. We have a time series and each pair of control and
stretch expressions. First, let's get an overview again (steps 7 and on in the previously
explained scheme):
1. Obtain the Rat ear expression data set
2. Compile gene sets (we'll explain in detail further down how we did this)
3. Conduct GSEA
4. Perform Permutation testing
The first step was performed at the Children's Hospital RNA expression facility. Some of
the key steps are explained in the Appendix.
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A gene set is a collection of genes that are somehow related. They can for example be
part of a common pathway or they can be part of the same putative pathway.
A number of the gene sets that were used were obtained from Mootha's previously
compiled and reported genesets reported in [54] and located at [55]. However, the
probesets compiled by Mootha are human HU-133A (a type of human genechip)
probesets. Thus, we had to convert these probesets to rat orthologs. We can convert
Affymetrix probesets from one genechip type to their orthologs at the Netaffx analysis
center at the Affymetrix website (simply by doing a batch query and outputting
orthologs).
Other genesets were obtained from geneontology [56] by typing key terms that may stand
for important pathways (eg. Angiogenesis, hypoxia etc). GeneOntology then output a set
of different 'hits' with relevantly named 'gene lists' or 'gene sets'. These links then gave
us the genes under that pathway.
However, our expression data is represented by probeset ID's not genes. A probeset is a
term for a set of 'probes' that represent a gene. They are 15 to 20 nucleotide long probes
that interrogate pieces of RNA that are obtained from the sample. The probes are chosen
so that they can uniquely identify one single gene [57]. Each Affymetrix genechip has
probesets for the genes that that chip can interrogate. There are multiple chips even for
each species.
As was mentioned above, Mootha's data are replicates at the same time point. Thus, there
are no pairwise comparisons to be made. In our case, we needed to conduct a pairwise
test. Further, we couldn't just take each time point (control and stretch) and obtain
anything meaningful from it, because after we run our GSEA analysis, we need to be able
to run a P value test that will give us an idea of how significant our gene set analysis is.
To run the P value test, we need to be able to shuffle our columns. We have eight control
and eight stretch columns. If we shuffle randomly, we'll on average get C(8,4) number of
shuffles or combinations which is [8*7*6*5/(4*3*2)]A2 = 4900 permutations which is
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well above 1000 permutes. If however we only had 7 time points we'd be short of being
able to obtain 1000 permutes. We'll explain further down how the permutations were in
fact carried out.
Therefore we decided to use the paired difference T statistic to rank our gene list. The
paired T statistic is given by,
t=(X- n) n(n -1)
(X -Yi) 2
i=1
To make computation easier, we squared this statistic and then ranked the genes. In the
above equation, X is the average value of the control set across a gene, and Y is the
average value of the stretch set across a gene. X = Xi - X and Y = Y - Y. 'n' is the
total number of entries of control or stretch for each gene (8 in our case).
We can perform two fundamentally different types of analyses if we keep the sign of
X - Y versus if we don't. Squaring the t statistic removes the sign, but we can always
insert it back in. Let's see what keeping the sign means.
Using the t statistic squared with the sign
If the stretch condition overall has a higher expression value versus the control set, then
X -7 Yshould give us a negative sign. Similarly, if the stretch condition expression is
lower than control, then X - F is positive. Thus, if we're looking for doing an analysis
where we try to rank genes by their degree of upregulation in the stretch condition, then
we should keep the sign in our squared t statistic, and we should rank the genes such that
the most negative values of the t statistic squared (with the sign kept) go to the top. While
if we want to do a downregulated analysis, we should reorder our genes such that the
most positive t statistic squared value (again with the sign of X - Y kept) going to the
top.
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Mootha's analysis [54]in fact only ran the first upregulated case mentioned above.
However, there can certainly be value in running the analogous downregulated analysis
as it can give us important insights into what genes (or gene sets and therefore pathways)
are suppressed in the system under study.
However, we can go one step further. We can in fact do a combined analysis where we
look for changes in expression regardless of sign. If the changes are big, then those
genesets should go to the top regardless of whether the genes in the genesets are up or
down regulated. Let's study this way of analyzing the data now
Combined up and down regulated gene set enrichment analysis using the paired
difference t statistic
By not keeping the sign in our t statistic squared, we're now essentially looking for
aggregate largest changes regardless of whether the changes come from up or down
regulation. For example, we may have a geneset that has members some of whom are
highly upregulated while some others are highly downregulated. Such a geneset may not
come up to the top in a simple up regulated or a simple down regulated analysis.
However, it may come up to the top if we do a combined analysis. For example (we'll go
into detail about this later), we found that hypoxia came up to the top using such a
technique. Using either the up regulated or the down regulated analyses alone would not
have allowed us to find this gene set. It may be highly important because its members are
most differentially expressed. However, their different signs mean that they don't show
up at the top of the signed analyses.
Once we rank our genes using either of the above analyses, we need to find a score for
the different gene sets that we have that will give us an idea of the importance of that
gene set (or pathway) in our analysis. Let's take a look at how such a score is found.
Finding the enrichment score (this is a normalized Kolmogorov-Smirnov Statistic
[54])
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Let's say next for illustration purposes that our data matrix has genes labeled 1 through
10 (our real dataset has 31099 genes or probesets). Let's say this geneset has within it
genes labeled 2, 7, 9. The unordered genes look like the following with the second
column showing hypothetical values of the t squared statistic calculated.
Gene label t statistic
squared
1 0.4
2 0.8
3 0.2
4 0.7
5 0.9
6 0.3
7 0.6
8 0.4
9 0.1
10 0.6
Let's say we want to find the enrichment score or ES for our geneset. Let's say that our
genes have been reordered based on the t statistic squared column. The following table
shows this graphically. The first two columns are reordered using the second columns.
The rest of the columns show conceptually how the enrichment score is obtained. In the
third column, we've marked where the gene set members are located. For clarity, the
fourth column has shown the formula for the Kolmogorov statistic. Note that the statistic
value is the same number for genes that are not members of the gene set group, and
another same number for members of the group. The statistic is then obtained with G
being 3 (number of genes in gene set) and with N being 10 (total number of genes in our
analysis).
The sixth column then computes a running sum starting at the first row. The enrichment
score is the maximum value obtained by this running sum.
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Gene t statistic Gene Kolmogorov Statistic value Running ES
label squared set Statistic sum
Gene 5 0.9 G 3
XN=- XN -0.65 -0.65
N-G 10 -3
Gene 2 0.8 x GXx= - = 1.53 0.87
G 3
Gene 4 0.7 G 3
XN=- XN=- -0.65 0.22
N -G 10-3__
Gene 7 0.6 x N -G 
__0 -3 1.5 .44
G 3
Gene 0.6 G 3
10 XN - XN =- - = -0.65 1.09
N -G 10 -3
Gene 1 0.4 G 3
XN = - XN = - = -0.65 0.44
Gene 8 0.4 G 3
XN =-XN = - = -0.65 -0.22
Gene 6 0.3 G 3
XN -G XN = -0.65 -0.87
N G 1-3
Gene 3 0.2 G
XN = -_
N -G
3XN=- = -0.65
10 -3
-1.53
We see in the above that the ES is 1.745743 (the highest running sum number). We see
that if all the members of the gene set are at the top of the list, then our ES will be a
maximum value. Second note that the Kolmogorov statistic can really only take two
values: one value when the gene is part of the gene set defined by 'X', the other value
when the gene is not part of the gene set XN (note also that this value is negative).
Further, X and XN are reciprocals of each other with XN also being negative. The
running sum always ends up at zero. We can see that if the gene set members were all at
the top with no non group member in between them, then the ES would be max at the last
member of the group. If all the gene set members were at the bottom, then the max ES
would be zero.
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Now, we'll take another example to find the ES for another geneset which has 2 values -
genes 5 and 4(remember the number of genes in a gene set can never be greater than the
total number of genes in the analysis. Also note that all genes in the gene set have to be
found in the total number of genes that we have. A good way to have a check on this is to
make sure that the running sum finally is zero at the last row (the reordered table above
has gene # 9 at the last row and we see that the running sum is zero).
G 7
Our new values for XN is - - = -1.527525
N-G 10 -7
1-7
and for X is 0 0.6546537. We'll again do the running sum and the ES for
7
illustration purposes. We already have our (hypothetical t squared statistic calculated-
this is only computed once). The running sum and ES for gene set 1 (we're calling the
gene set we started with gene set 1 now) are copied from the table above. Gene set 2 is
shown next. We've deliberately chosen the gene numbers in gene set 2 to show that the
higher up the gene set members are, the higher the ES will be, and this is independent of
the gene set size (gene set two is smaller than gene set 1). The calculations for gene set 2
are shown in grey.
Gene t statistic Gene set Running ES
label squared 1 sum
Gene5 0.9 -0.65465
Gene2 0.8 x 0.872871
Gene4 0.7 0.218218
Gene7 0.6 x 1.745743 <-
GenelO 0.6 1.091089
Genel 0.4 0.436435
Gene8 0.4 -0.21822
Gene6 0.3 -0.87287
Gene3 0.2 -1.52753
Gene9 0.1 x 0 (round
off
neglect)
The above (hypothetical) analysis can be extended to any number of gene sets. Looking
at gene sets rather than individual genes reduces the noise in our system by a factor of
-'1 where G is as above the number of genes in a gene set [54].
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In our system, we had 173 gene sets. We'll explain the findings in our results section in
this chapter.
After computing the ES for all the gene sets in our system, we look for the gene set with
the highest ES. This gene set (or pathway) then is our most important pathway in our
analysis. However, this is not the end of the story. Usually when we find a certain
finding, we want to be able to state what level of confidence we have in our finding, that
the finding is in fact real and not the result of a chance occurrence. In other words, we
want to find the P value of our analysis. We want to say what is the chance that the gene
set we obtained (the one with the highest ES) is a chance hit.
Carrying out the permutations
The name, permutation test, can be misleading. It may seem to imply a 'simple'
permuting or shuffling of the data. That is not the purpose of the permutation test. In a
permutation test, the goal is to be able to discriminate between two conditions. Are the
differences between two conditions real or are they the effect of chance occurrence?
Therefore the 'shuffling' that needs to be performed has to be able to 'ablate' the
structure in the data that gives us a difference only if the difference is real. If the
difference isn't real, the ablation will do nothing or will do far less.
Let's see how this can be applied to our system.
Our system is composed of two rectangular matrices (one if we normalize the data)-one
is the control matrix, the other is the stretch matrix. We want to be able to tell if the
stretch matrix condition in a certain row (say corresponding to gene 'x') is really different
from the control matrix condition in the corresponding row (also pertaining to gene 'x').
Now if there really is a difference between the two groups, then in essence this difference
will be a greater difference than we would have if we shuffled a few members between
the groups, because by doing so, we're averaging out the 'real' difference that we see
(this idea follows along the lines presented by Good [58]).
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If however, there is no difference between the groups, any shuffling will not really
produce much difference. In fact, the shuffling may actually produce more of a difference
if the right numbers come together. Thus, the 'random' shuffling of the class members (or
labels as some call them) may end up producing 'real' differences. This is the idea behind
the permutation test. If the random shuffling of class members is able to give us
significant differences enough times, then that means that the difference that we observe
in the original data aren't real-they can be the product of a chance occurrence. Further,
this type of a test is able to discriminate between real differences (by quashing the
difference in a random shuffle) versus artifactual (or putative differences) that aren't
quashable (and in fact may be exacerbated) in the shuffled data.
The above reasoning also answers why 'rearranging' the rows in our data doesn't do what
we want it to do. Rearranging the rows cannot discriminate between real differences and
supposed differences. It is not testing for differences between GROUPS. Remember that
we're ranking the genes by some metric. The ranking is the RESULT of the operation of
this metric. The metric is supposed to be able to identify differences between the groups
(control versus stretch).
The value of the metric then gives the ranking order. If we were to simply shuffle the
ranking order, we've really not asked to test for a difference between the two groups.
This rearrangement will always make the data look like it is randomized. In that sense
(see later) all gene sets will find themselves at the top some portion of the time. Rather
than testing for a chance occurrence of a geneset coming to the top because it really isn't
able to discriminate between groups, the chance of any geneset coming to the top
becomes equal to any other!
In the first column we have the genes (one through 31099). The eight columns after the
first are the eight time points we have.
Why do we keep each condition together? In other words, why do we swap whole
columns rather than one member of a column only? Because in one sense each column is
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a 'condition'. When we test a drug for its effects on sick people versus the effect of a
placebo on another set of sick people, our subjects are people. We can think of this
person as being comprised of many many genes (which he is-but we're thinking of the
genes in a way where we think of them as forming a complete group). For example, if we
wanted to test the strength of a table in terms of its being able to withstand a certain
weight, we consider each part of the table as moving together. For example, let's say we
have 6 tables (3 in one group and 3 in another), and we identify 12 'genes' or 'parts' of
each table as 'identifiers' that can possibly speak to the strength of the table, when we
'shuffle' the tables between the groups to see if they are really different, we are really not
allowed to shuffle parts of one table with parts of another table. This is because the
property that we're looking at (strength) is a reflection of how each part of the table is
connected to the rest of the table.
Analogously when we say we have six people, 3 women and 3 men, and we're looking to
see if there is really a strength difference between the two groups, we're not really
allowed to give one man's legs to a woman, because then we really haven't tested for
differences between the WHOLE man and the WHOLE woman.
According to Phillip Good [58] in his book on permutation tests, first we identify the
hypothesis and the alternative of interest. In our case, the hypothesis could be that
stretching the rat ears really doesn't do anything versus the control case. The alternative
hypothesis is that stretching does do something.
Next, according to (1), we need to choose a test statistic. We chose the t statistic. We
calculate the test statistic AND then rank our genes. This ranking gives us our VALUE
that we will study further (the value really is a record of all the genes in their respective
positions with the rank reordering).
What essentially Good is saying is that if there really is a difference between the two
conditions, then this VALUE will be an extreme condition, and a mixing of the samples
will never replicate (or very rarely do so) the extreme condition. However, if the
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difference is really not there, then a mixing will be the SAME as if we never mixed the
labels (the label is really the one test condition) and we will replicate our reordering
many times possibly.
Possible problems with the way the enrichment score is computed
But here's the real problem with the way we're doing the permutations. We're looking
for the number of times a certain geneset goes to the top. We're not looking for how far
away from the extreme its enrichment score changes. For example, let's say geneset A
gets an enrichment score of 100, and let's say that swapping labels shifts the difference
between the two conditions somewhat. However, if the enrichment score of geneset A is
much above the next geneset (say geneset B), its 'diluted' ES score may still turn out to
be far higher than the 'possibly increased' enrichment score from geneset B. Thus, what
we should really look for is a shift away from the enrichment score for each geneset in
each of the 1000 permutes rather than the maximum enrichment score obtained by each
geneset in each of the 1000 permutes.
If two things are really not different, then switching things will not change their
difference. However, if two things are really different, then switching things will change
their difference. Then since the difference is lower, this 'permuted' condition will not be
seen at the highest level in GSEA.
Here's the problem though. If there are say 8 conditions, by switching one pair at one
time, we're really not CHANGING the difference too much, since one pair swap may not
make too much difference (in our test, we're on average swapping 4 labels, so we're
actually doing better).
My concern really is that if geneset A is so far different that swaps still maintain some
difference, and the rest of the genesets are so far below that they never obtain even close
by ES values, then geneset A will still come out on top, even though its ES value has
gone far from the extreme that it started out with.
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This above condition may happen when the ES scores are not somewhat continuously
distributed in the non permuted calculation. In our downregulated set, the ES's come out
to be somewhat continuous. However, in our upregulated set, the first two are abruptly
different from the rest, and therefore they might have a tendency to still be enriched even
though the permutes are 'diluting' their ES's very highly. Thus, in future work, it may be
instructive to try to find a distribution of the ES values in each of the 1000 permutes and
see where in that spectrum the non permuted ES falls. This may be a more reliable P
value measure.
However, overall the P values should show somewhat what is happening in terms of
whether the geneset if significant or not!
Now we look at row swaps and whether these are valid. What will a row swap do? A
random row swap really doesn't DIFFERENTIATE whether the two test conditions are
the same or different. The row swap will always swap randomly. It will never rank the
genes the same way (unless that happens by chance). Thus, our VALUE or the rank order
we obtained with the non permuted data is always permuted regardless of difference
between our two test conditions. We always pass the permute test since we're now doing
random orderings of our genes. It is not that this test is bad because it is too generous in
passing all our genesets. It will make all the genesets have almost the same P values (if
we truly rearrange the rows randomly)-assuming as seems reasonable that geneset
length doesn't affect their ES scores. The test is bad because it simply doesn't let us pass
the genesets when there is NO difference and pass them when there is a difference. In
other words, the test is bad, because it doesn't let us discriminate between the two
conditions. It completely bypasses the question of a test between the conditions. Thus,
this test in randomly allocating the rows is useless.
Let's explore the idea of the P test further. What is the ranking of our genesets by
enrichment score in the non permuted dataset really telling us? It is telling us that the top
ranked geneset is the most significantly different between the stretch and control
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conditions. The other genesets in turn are NOT significantly different between the stretch
and control conditions. Thus, the top ranked geneset sets an upper bound on the P value
in a sense. So if the P value for this geneset is extremely low-implying that this geneset
passes the test for DIFFERENCE between control and stretch-then it is possible that
genesets below it MAY also pass the P value test (if their P values are low enough-they
can be higher than the P value of the top ranked geneset from the non permuted set if they
are close enough in ES score to the top ranked non permuted dataset geneset). However,
if the top ranked geneset in the nonpermuted dataset does NOT pass the P value test-
implying that there really is no difference between the control and stretch conditions in
this geneset-then really none of the genesets below it CAN pass, since the genesets
were ranked based on a t statistic of the difference between the two conditions.
Thus the top rated geneset (in the non permuted dataset) sets the bar on the rest of the
genesets. This top geneset decides if the rest of the geneset CAN be allowed to pass or
CANNOT be allowed to pass depending on whether it itself passes the P value test!
We have to keep each column intact in our permutes, because each column is one
condition. Essentially, we've created 8 pseudo-replicates in each condition (Control and
Stretch). The reason we call these replicates 'pseudo' is that each of the samplings occur
at different time points. The samplings are therefore not repeats at the same time and
conditions.
Permutation testing implementation
Here's how the permutation test was implemented (perl was used to generate the whole
code-see the Appendix):
Let's say our data matrix looks like the hypothetical example shown next:
1. Generate a random number for each stretch column (shown in the top row
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0.4 0.1 0.3 0.6 0.2 0.8 0.7 0.9
Stretch Time 1 Time 2 Time 3 Time 4 Time 5 Time 6 Time 7 Time 8
Genel S11 S12 S13 S4 S15 S16 S17 S18
Gene2 S21 S22 S23 S24 S25 S26 S27 S21
GeneN SN1 SN2 SN3 SN4 SN5 SN6 SN7 SN8
2. Sort the random numbers largest to smallest (keeping the columns associated with
their corresponding random number).
0.9 0.8 0.7 0.6 0.4 0.3 0.2 0.1
Stretch Time 8 Time 6 Time 7 Time 4 Time 1 Time 3 Time 5 Time 2
Genel S18 S16 S17 S14 S11 S13 S15 S12
Gene2 S21 S26 S27 S24 S21 S23 S25 S22
GeneN SN8 SN6 SN7 SN4 SNI SN3 SN5 SN2
3. Next generate random numbers for each control column.
Control
Genel
Gene2
GeneN
0.3
Time 1
CI1
C21
CNl
0.1 0.5 0.4 0.2
Time 3 Time 4 Time 5 Time 6
C13 C14 C15 C16
C23 C24 C25 C26
CN3 CN4 CN5 CN6
4. Swap with the newly paired stretch column (in grey above) only if the random
number is larger than 0.5 (we're generating numbers between 0 and 1).
5. After the swap we obtain the following stretch and control matrices:
Final stretch matrix
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Stretch
Gene1
Gene2
Time 8
S18
S21
GeneN SN8Kt
Final control matrix
Control
Genel1
Gene2
Time 1
C1l
C21
GeneN CN1
Time 7 Time 4 Time 1 Time 3
S17 S14 Si S13
S27 S24 S21 S23
SN7 SN4 SNI SN3
Time 3 Time 4 Time 5 Time 6
C13 C14 C15 C16
C23 C24 C25 C26
CN3 CN4 CN5 CN6
The above then gives us a permute (where we've switched classes-the classes being
control and stretch) randomly. For each permute, we go through and calculate the
enrichment score (as we discussed above) for each of the 173 gene sets that we have.
Finally, we find the gene set with the highest enrichment score. This gene set then is
counted once as having the highest enrichment score.
We run the permutation test 1000 times, each time findout the gene set with the
maximum enrichment score (in our code that is given in the Appendix we implemented
this by 'pushing' the gene set into a vector each time it obtained the highest enrichment
score, and then counting the instance of each gene set in this vector at the end of the 1000
permutation tests).
We'll present the results of the gene set enrichment analysis for each of the three ways
we performed the GSEA (up regulated only, down regulated only, and combined up and
down regulated later). Next we'll illustrate how we attempted to find the 'right' time
points between two time points (2 hour and 24 hour) that were inadvertently switched by
the microarray facility. We were unsuccessful in determing which time point is which.
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Switched time points
The two hour stretch and 24 hour stretch time points were inadvertently switched by the
lab that handles the microarray hybridization process. The process was attempted to try to
deduce which of the two (stretched) time points is which.
Saban et al [59] studied the time course gene expression of urinary tract inflammation in
response to the placement of LPS in a mouse model. They built up 15 clusters of different
genes that were differentially regulated over different time periods. Clusters 7, 9, and 10
were mentioned as being upregulated at earlier time points peaking within 4 hours and
then declining by 24 hours. To see if these three clusters could unambiguously tell us
which of the two scrambled time points is which, we assumed that one of the time points
is the 2 hour time point and the other is the 24 hour time point. We then took ratios of the
two with their respective controls (which are not scrambled). Next we made the opposite
assumption and took two new ratios.
Next we checked for 39 genes that seemed to have a corresponding probe set ID at the
affymetrix website. Unfortunately, we found an almost even split of 19 to 17 between the
two assumptions (the reason these two numbers don't add up to 39 is that at times both
assumptions led to a concurrent down or upregulation). The two numbers 19 vs 17 almost
make it seem like the genes looked at are really not important in the time series and that
the expression pattern is random with respect to deciphering the two time points.
It could just be that inflammatory genes are not really being over or under expressed with
stretch (we will test this rigorously by applying GSEA by treating each cluster from the
paper as a gene set). For now, therefore, we will discard these two time points and find
clusters of genes by using paired GSEA, PCA, and SOM. The clusters that will be
obtained at earlier (versus those obtained later) will then be used to find out if the two
time points can be correctly placed unambiguously.
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Creating the GSEA code without using high dimensional matrices
Initially the code was constructed by trying to build a set of matrices that added on
columns each time a different computation was performed. Thus, each new computation
had to carry all the previously loaded data into the next run of the algorithm. This worked
when we calculated only one enrichment score. However, this technique was not very
useful in performing 1000 permutations and at the same time creating a 1000 dimensional
matrix each 2D section of which had 31099 by approximately 180 entries (each gene set
was allocated a column). The memory soon ran out!
A much sparser solution was obtained by recognizing that first we didn't have to match
each gene set with the reordered array with each new ordering. The two Kolmogorov
statistic values are only dependent on the size of the group (the gene set) and the total
number of genes in our analysis. Both of these stay the same for our whole analysis (the
only way the total number of genes will change is if the chip is changed.
To see how we conducted the sparser solution, let's see how the genesets were loaded
into Perl. We'll then study how these gene set files were transformed so that they had the
Kolmogorov statistic on each line corresponding to the
We start out with text files, each text file having the list of probesets that make up one
gene set. One extra text file stores the names of all the text files with the gene set names,
one name per line. Let's see this graphically:
Genesetl.txt (say-in our system, we named the file based on the geneset name-for eg.
angiogenesis.txt). Note that the size of a geneset given by G with the corresponding
subscript is not constant across genesets. The made up gene numbers are given for each
gene set.
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Gene 37
Gene 125
Gene 77
Gene 20000
Gene G1
Geneset2.txt (this could for example be 'Responseto mechanicalstimulus.txt')
Gene 1000
Gene 10
Gene 30000
Gene 345
Gene G2
Gene 15467
Gene 19000
Gene 897
Gene 17000
Gene Glast eene set
After we created all the geneset text files, we created one text file called 'gsetfiles.txt'.
This file had a list of all the gene set files, shown illustratively below:
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gsetfiles.txt
Genesetl.txt
Geneset2.txt
Geneset3.txt
Geneset(last geneset
name).txt
Whenever we wanted to load the geneset files, we would first open a file handler in perl
that would load the gsetfiles.txt and then we'd open filehandlers to each of the files listed
in the gsetfiles.txt to access all the gene set text files. We'd then load each gene set gene
into a suitable array to operate on it.
Early on, it was recognized that given that our gene sets are by definition heterogeneous
both in terms of the numbers of genes they contain and the types of genes they contain, it
would be computationally much too intensive to sort the the genes by the ranking metric
(the t statistic squared as we used it or the difference metric that Mootha used) and then
look for the corresponding entries that match with the members in each gene set. This
step was made tractable by doing the following. Each gene (or probeset label) was
replaced by an index running from 0 to 31098 (for a total of 31099 genes or probesets).
For each geneset, we created a new file that had the appropriate Kolmogorov statistic in
each row replacing the gene name. Let's look at this graphically:
Before we show the figures, it is important to remember that the gene set files to start
with only have G1, G2, ... , Gn entries where the subscript refers to different genesets. So
for example, while gene set 1 (G1) may have 20 genes (one gene per row in the text file),
gene set 2 may have 14 entries, gene set 34 may have 140 entries and so on. However,
after we do the transformation, each gene set will have exactly 31099 entries. To make
our illustration more concrete, let's use made up numbers. Let's say we have:
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1. A total of 10 genes or probesets in our analysis, and let's say we have
2. Three gene sets, with
a) gene set 1 having 2 members (genes 2, 9-we can't have duplicates),
b) gene set 2 having 7 members (genes 7, 4, 9, 8, 10, 1, 5), and
c) gene set 3 having 5 members (4, 2, 6, 1, 7).
We're now ready to see this graphically (see Figure on next page):
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Generating the transformed Geneset.txt files (for
example, angiogenesis.txt , hypoxia.txt etc)
Geneset_1.txt
text file before
transformation
Array of all genes to
see where Geneset_1
has correspondence
Call this file
expression .txt
Gene9 Index (location) Name of
GNe of gene gene
Gene2 - Gene] Oo
1 Gene2
2N Gene3
3 Gene4
4 Gene5
5 Gene6 e
6 Gene7 /
7 Gene8 /
8 Gene9
9 Gene 10
Compute,
N-G
X = -=
G
= 2 when a
member of
Gene set_ .txt
matches the total gene
array and place this
value at locations 1 and
9. At all other
locations, where our
Geneset_1 .txt has no
hit on the 'array of all
genes' list, we place
the alternate
Kolmogorov statistic
value given by,
XN =
G
2
-
-0.510-2
New
Gene set_ .txt
file, with -0.5
at locations
(corresponding
to 'array of all
genes' list)
where there is
no hit (shown
in red), and 2
where there is
a hit (shown in
blue). Note
that the
transformed
file has 10
entries
-0.5
2
-0.5
-0.5
-0.5
-0.5
-0.5
-0.5
2
-0.5
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After generating the transformed file (which was named the same as the original file), we
are ready for the analysis where we compute the permutations.
So let's start with our expression file (which we named expression 1.txt) given above.
Now let's add a column next to this file with hypothetical t statistic squared values:
ExpressionL. txt
Index (location) Name of
of gene gene
0 Genel
1 Gene2
2 Gene3
3 Gene4
4 Gene5
5 Gene6
6 Gene7
7 Gene8
8 Gene9
9 GenelO
t statistic
squared
0.5
0.4
0.9
0.1
0.6
0.7
0.2
0.95
0.3
0.8
Now we load our expression L.txt file into perl and reorder it based on the t statistic
squared values. Rows stay together. Our index is thus shuffled as shown next:
Let's say we call the new array reordered array. To find the running sum, all we do is
reference the gene-set.txt file through the index. Remember also that the new reordered
array has its own index that starts at zero and goes to 9 (shown on left).
Reordered
Array index
0
1
2
3
4
5
6
7
8
9
Index (location) Name of
of gene --- -genr-
7 Gene8
2 Gene3
9 Gene10
5 Gene6
4 Gene5
0 Gene I
1 Gene2
8 Gene9
6 Gene7
3 Gene4
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t statistic
square
0.95
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
Reordered_array
column 0
Thus, for example, if we have a 10 times 'for loop' to run through our reordered array
(and let's say we load our (transformed) gene_set file into an array called
gene set_array), we can reference the first entry by performing
'gene setarray[Reordered-array[0]]' to find the first running sum entry and so on.
The rest of the code (which is shown in the Appendix) was also made sparse by calling a
subroutine that found the gene set with the highest enrichment value. This gene set name
was then the only 'value' that was output back from the subroutine to our main program.
This way our memory usage was kept to a bare minimum.
Self-organizing maps: A way to test validity of the gene set enrichment analysis that
we performed
The self-organizing map was developed by Teuven Kohonen [60]. It involves finding
closely matching patterns in a dataset. Essentially the method starts out by seeding with
random vectors at certain locations and then inputting the data vectors at each of the
locations. The smallest distance between the seeded vector and the dataset vector within a
certain 'circular' range then gives us a new seeding vector that replaces the old vector
(the new vector is the data set vector that gave us the smallest distance to the random
starting vector). We can reseed the system with the data set vectors and continue the
iteration until we converge.
The SOM then can classify data into classes based on the similarity of the vectors in each
class.
GenePattern software from the Broad institute website [61] was used to find the most
important genes that were up or down regulated. Although our data is noisy and therefore
these genes are probably false positives in some sense, it is still useful to use these gene
groups (one up regulated and one down regulated) to validate our gene set enrichment
analysis because the two sets we obtain are essentially 'trained' on our data, but are
obtained independently of our use of the GSEA.
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We found that the up regulated genes from SOM were indeed enriched at the top of the
up regulated GSEA, and that the down regulated genes are enriched at the top of the
down regulated GSEA. Further, both these gene groups (or 'gene sets) came to the top in
our combined analysis validating our analysis.
Now that we've discussed GSEA (including the permutation testing), let's look at some
of the results that were obtained.
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Results (GSEA)
First let's look at the combined up and down regulated GSEA
Combined up regulated and down regulated GSEA
The following table shows the enrichment scores for the first ten genesets along with
their P values. The Appendix has the whole table with the enrichment scores along with
the three different P value iterations for each gene set.
Gene Set
hypoxia.txt
responsejto-mechanicalstimulus.txt
c3_U133_probes.txt
MAP00340_Histidinemetabolism.txt
c27_U133_probes.txt
MAP00280_Valineleucineandisoleucine-
degradation.txt
c23U 1 33_probes.txt
c6_U133_probes.txt
mitochondrHG-U133Aprobes.txt
MAP00140_C21_Steroidhormone-
metabolism.txt
Enrichment
Score
321.0
310.3
308.1
304.6
301.7
283.6
278.6
254.7
252.7
240.8
We see that hypoxia comes to the top in our combined analysis, and we see that its P
value in the three iterations are very small, while we note that
response tomechanicalstimulus finds itself second highest. Although this is reassuring,
we should note that its P value is a bit high, telling us that it may have come close to the
top as a chance event in our analysis.
Up regulated GSEA
The following table shows the results from the up regulated GSEA
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P value
1st iter.
0.001
0.014
0.018
0.003
0.016
0.008
0.013
0.01
0.005
0.002
P value
2nd iter.
0.003
0.015
0.018
0.004
0.016
0.011
0.01
0.017
0.01
0.006
P value
3rd iter.
0.007
0.016
0.018
0.004
0.017
0.01
0.012
0.014
0.009
0
Enrichment
Gene Set Score P value
responsetomechanicalstimulus.txt 560.2 0.085
c26U 1 33_probes.txt 415.6 0.014
c6_U133_probes.txt 343.6 0.023
c3_U133_probes.txt 336.8 0.003
Hum_FbSerumEarlyTF.txt 335.1 0
OXPHOSHG-U1 33A-probes.txt 328.9 0.131
c27_U133_probes.txt 289.0 0
mitochondrHG-U133Aprobes.txt 283.7 0.018
MAP0071OCarbonfixation.txt 274.4 0.004
c14_U133_probes.txt 265.8 0.002
The high P value obtained by response to mechanical stimulus means that this gene set is
not significant in the up regulated analysis
Down regulated GSEA
The following table shows the results of running the down regulated GSEA
Gene Set ES P value
MAP00280_Valineleucineandisoleucinedegradation.txt 346.6 0.008
MAP00340_Histidinemetabolism.txt 288.9 0.005
MAP0031 0_Lysine-degradation.txt 284.6 0
MAP00380_Tryptophan-metabolism.txt 274.2 0.002
MAP00380_Tryptophan-metabolism-.txt 274.2 0
MAP00632_Benzoatedegradation.txt 270.5 0.01
hypoxia.txt 263.3 0
MAP00562_inositol-phosphate-metabolism.txt 261.8 0.004
MAP00052_Galactosemetabolism.txt 242.5 0
MAP00521_Streptomycin-biosynthesis.txt 239.2 0.001
As above the full table is in the Appendix. We see here that the highest gene set has a low
P value and (lower than 0.05) therefore is significant. We also note that hypoxia is at
number 7. However, we see that Mootha's gene sets had a duplicate (numbers 4 and 5
above). Therefore, Hypoxia is actually at number 6, quite high and this points to the fact
that hypoxia is more downregulated than upregulated. We'll discuss hypoxia at more
length in the discussion to follow.
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Discussion
The definition of hypoxia from [62] is:
"Reduction of oxygen supply to tissue below physiological levels despite adequate
perfusion of the tissue by blood."
We found that in our combined gene set analysis, hypoxia came to the top, while in the
down regulated analysis, hypoxia was quite close to the top. Many investigators have
looked at the effects of hypoxia on cells grown in vitro. For example, Lu et al looked at
rat pulmonary artery smooth muscle cells grown in vitro and showed increase in number
of cells and increase in collagen synthesis under hypoxic conditions [63].
An in vitro study by An et al [64] studied the effects of hypoxia on rat pulmonary
endothelial cells. The authors found increases in cell stiffness and traction forces exerted
by cell on its substrate.
Another study by [65] looked at VEGF production by oral and epidermal keratinocytes in
vitro. Much higher levels of VEGF protein and mRNA were reported by the authors in
epidermal keratinocytes than in oral keratinocytes after 18 hrs of hypoxia.
Sahota et al studied "a number of simple strategies to improve
angiogenesis/vascularization using a tissue-engineered model of skin to which small
vessel human dermal microvascular endothelial cells were added". The variables studied
were "cell type, angiogenic growth factors, the influence of keratinocytes and fibroblasts,
mechanical penetration of the human dermis, the site of endothelial cell addition, and the
influence of hypoxia"... "Two factors were identified that significantly enhanced
endothelial cell penetration into the dermis: hypoxia [bold added for emphasis] and the
site of endothelial cell addition." [66].
A common thread among the above cited studies is that in vitro, hypoxia induces
pulmonary artery smooth muscle cells to become more proliferative, it induces
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pulmonary endothelial cells to exert higher traction forces, that it increases angiogenesis
and vacsularization of skin muscle cells, and that it induces VEGF expression in
keratinocytes.
Hypoxia inducible factor (HIF) is a transcriptional factor that turns on genes that respond
to hypoxia [67]. Kondo et al [67] show that HIF may play an important role in bladder
and renal cancer cell proliferation and angiogenesis. Schlueter et al [68] state that tumor
progression causes hypoxia conditions that upregulate genes that induce vascular
proliferation.
It would seem reasonable that when we stretch rat ears, that cell proliferation would
occur. Further, work at the Orgill lab has shown that rat ear stretch leads to growth in
vasculature. However, the above lines of evidence which are extracted from in vitro
studies seem to show that hypoxia is good for cell growth. On the other hand, hypoxia
genes also are turned on in vivo under turnorigeneses and cancer like conditions.
Thus, it could be that there are separate pathways involved in neovascularization in
tumorigenesis versus cell stretch and that the pathway involved in cell stretch is the one
that suppresses hypoxia genes in our system. Further, in vivo effects because they are in
balance with the rest of the organism are not extractable from in vitro systems. Thus,
although hypoxia may confer certain benefits (although the metric of studying these
benefits may themselves be uni-dimensional-for example, is cell growth always good?
It certainly isn't when there is a tumor in the body) in vitro, it may do the reverse in vivo.
To understand the hypoxia geneset further, a time series analysis of hypoxia was
conducted. Next, the hypoxia geneset was dissected into upregulated and downregulated
components. A literature search combined with further runs on newer genesets created
based on the literature search revealed possible mechanisms by which the hypoxia
geneset may modulate tissue response to forces.
Let's look at the normalized time study of hypoxia first.
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Time series study of 'hypoxia' looking for possible changes in regulation (down to
up)
To gain an understanding of the analysis further, a time series study was conducted to see
global patterns of gene expression. As can be seen in the graph below, there are tandem
movements of genes each of which is given by the series labels (there are 15 genes in
hypoxia). Four genes show remarkable in step movement at the earlier 9H time point.
This seems to be the only interesting pattern that can be gleaned from this figure.
A normalization of stretch versus control was performed and then the hypoxia genes were
plotted over time. There are 15 genes in hypoxia (each series in the chart below refers to
a gene. The results are shown below.
hypoxia genes normalized plotted
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To gain an understanding of which genes in hypoxia were upregulated in stretch versus
control (over time), the t statistic was calculated. Its reordering gave the following
results:
86
hypoxia genes (blue upregulated, red downregulated)
Probe Set ID Gene Title Gene Chromosomal Entrez t score
Symbol Location Gene
1368286_at solute carrier family Slc2a8 3p11 85256
2, (facilitated Entrez
glucose gene
transporter)
member 8 5.243583
1370080_at heme Hmoxl 19p11 24451
oxygenase Entrez
(decycling) 1 __ene 4.126249
1381936_at calcium/calmodulin- Camk2g 15p16 171140
dependent protein Entrez
kinase I gamma gene 2.178111
1371719_at bromodomain- RGD:1303324 20p12 294276
containing 2 Entrez
gene 1.360505
1371289_at -0.19267
1375650_at bromodomain RGD:1307282 7q11 362844
containing 4 Entrez
(predicted) gene -0.25929
1368322_at superoxide Sod3 14q11 25352
dismutase 3, Entrez
extracellular gene -1.15325
1369703_at endothelial PAS Epas1 6q12 29452
domain protein 1 Entrez
gene -1.40849
1387605_at caspase 12 Casp12 8q11 156117
Entrez
gene -1.41842
1387818_at caspase11 Casp4 8q11 114555
Entrez
gene -1.58963
1387667_at nitric oxide Nos2 10q24 24599
synthase 2, Entrez
inducible gene -2.31805
1373916_at CDNA clone
IMAGE:7303964,
partial cds -2.72021
1369186_at caspasel Casp1 8q11 25166
Entrez
gene -2.77534
1374863 at -2.99321
1369307_at E1A binding protein Ep300 7q34 170915
p300 Entrez
__genre -4.45035
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Next, we're ready to collect inferences drawn from the literature search and put them
together with further geneset enrichment analyses using newer genesets obtained from
conclusions drawn from the literature search.
The response of tissue to stress is an important starting point for the literature search. A
good example of this is reactive hyperemia and we begin with this.
Reactive Hyperemia
To gain an understanding of our system, it was decided to study the tissue response to
mechanical stress, specifically the response of blood vessels to reactive hyperemia.
What is reactive hyperemia?
This is a response of blood vessels to a blockage in blood flow. For example, when a
tourniquet is applied to the arm, blood flow is blocked. When the blood flow is
reestablished, the increased blood flow [69] causes a rise in shear stress that then causes
calcium influx in the endothelial cells, which then upregulates (nitric oxide) NO
production, and this causes a relaxation of smooth muscle cells leading to an increase in
the diameter of the vasculature (or vasodilation). It is believed that nitric oxide is
upregulated during reactive hyperemia [69]. However, this mechanism of action is not
established, and the role of NO in reactive hyperemia is largely unknown [70].
In our system, nitric oxide synthase II is being downregulated heavily. An attempt was
made to explain this through pathway mechanisms. However, Zhao et al have shown that
nitric oxide concentration does not increase during reactive hyperemia [71]. Wong et al
have also obtained similar results in showing that in the cutaneous circulation (which
itself is quite relevant to this thesis) NO synthase inhibition does not alter the reactive
hyperemia response.
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This leads to a possible conclusion that contrary to what is believed by many (that
reactive hyperemia is mediated through NO production), it may be that NO mediates
reactive hyperemia in certain locations and contexts (for example, Tagawa et al's and
Wong et al's studies looked at the production of NO during exercise) while in other
contexts it may not be very relevant.
It would be valid to conclude (we'll see why later through references) that NO production
is a response to cell damage mediated by pathogens, tumor or other possible 'living'
agents that need to be neutralized through the action of the innate immune system. Other
pathways that may damage the cell (such as UV radiation) also can cause NO production
[72]. However, cell stretch may be one pathway of cell injury that does not upregulate
NO production.
Heme Oxygenase I
In our system, however, Heme Oxygenase I, an enzyme with cell protective functions is
highly upregulated, while nitric oxide synthase II is heavily downregulated. It is known
that HO is upregulated by the production of NO [73]. However, HO itself is a negative
regulator of NO. According to Turcano et al [74], induction of HO by hemin strongly
inhibits NO production of LPS-activated macrophages.
Since HO is a negative regulator of NO, if HO is upregulated independently of NO
production, then NO will be strongly downregulated. This then may explain why HO in
our system is upregulated while NO is strongly downregulated. However, see the caveat
at the end of this section.
"HO-1, an inducible form of HO, is thought to act as an endogenous antioxidant defense
mechanism" [75]. "Nitric Oxide Induces Heme Oxygenase-1 Gene Expression and
Carbon Monoxide Production in Vascular Smooth Muscle Cells" [76]. "The Rat Heme
Oxygenase- 1 Gene Is Transcriptionally Induced via the Protein Kinase A Signaling
89
Pathway in Rat Hepatocyte Cultures" [77]. Many pathways lead to heme oxygenase I
expression through renal injury [73]. The following figure is reproduced from [73]:
Renal Injury
Ischemia-reperfusion
Nephrotoxins, Sepsis
Rhabdomyolysis
Transplant rejection
Glomerulonephritis
Heme Hypoxia NO Cytokines Growth ANG 11Endotoxin factors
Induction of HO-i
Thus, if mechanical stress can cause an upregulation in cytokines or growth factors which
cause an overexpression in HO-1, then because HO-1 acts upon NO to downregulate it,
we may get NO repression.
Heme Oxygenase itself has been implicated in various disorders [78]. The following
figure is reproduced from [78]:
dHeme oxygenase immunosuppression
Isohemia and -[
reperfusion Lung dse s
Hypertension
Endotoxemia
Cardiomyopathy,
heart failure, and Transplantation
hypertrophy
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"High levels of HO-1 are frequently detected in various pathological states and generally
in states of cellular oxidative stress." [79].
"HO-I is a member of the heat shock protein family, which catalyzes the initial rate-
limiting step of heme degradation to CO and biliverdin" [80].
Nitric Oxide
NO exhibits toxic effects, but the mechanisms are unclear [81]. Although mechanisms of
the toxic effects exhibited by NO are unclear, various types of proposals [81] have been
reported, including "monoADP ribosylation, S-nitrosylation of glyceraldehyde-3-
phosphate dehydrogenase, inhibition of mitochondrial enzymes such as cis-aconitase,
inhibition of mitochondrial electron transport chain, inhibition of ribonucleotide
reductase, DNA damage, and activation of poly(ADP-ribose) synthetase."
NO is cytotoxic leading to apoptosis and is used in innate immunity and "tumor and
pathogen killing" [82].
Murphy et al hypothesize that SOD [which is also part of the hypoxia geneset] promotes
the production of NO from NO~ by accepting an electron from the latter [83]. This can be
shown by the following pictorial:
SOD
In stretching cells, cell damage may lead to upregulation of heme oxygenase. Since there
is no pathogen attack or tumor growth, NO production through SOD pathway isn't
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initiated. Thus, since HO itself suppresses NO, the levels of NO are downregulated below
baseline levels.
Keratinocytes' response to stretch
Yano et al have shown that in vitro, Keratinocytes respond to mechanical stretching by
proliferating [84]. Zheng et al report "that FGF-2 and IGF-l [which are growth factors]
may regulate the proliferation step during [inner ear] hair cell development and
regeneration." [85].
In this context it is interesting to note that "Platelet-derived growth factor suppresses and
fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured
smooth muscle cells." [86]
To test whether in our system PDGF is in fact upregulated while FGF may potentially not
be so upregulated, queries were performed at "NetAffx" [87] for PDGF and FGF
probesets corresponding to the RAE 230 2.0 rat chips. Gene sets were then constructed
out of the probeset ID's obtained.
These genesets were then input into the UPregulated gene set analysis to see if they show
high ES scores. Interestingly, the PDGF geneset obtained an ES of 152 (FGF had a score
of 115). PDGF and FGF had ranks 49 and 70 out of 177 total genesets).
PDGF is a growth stimulant which is seen in monocyte supernatants [88]. We can thus
conclude that indeed cytokines that cause cell proliferation are upregulated in our
system and that there is cell growth in our system.
It is not clear whether there is tissue injury in the system
Next, we wanted to see if tissue injury cytokines may be upregulated (since nitric oxide is
a mediator of cell defense and this is downregulated, we'd expect cytokines that feed into
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nitric oxide synthase to be not so very upregulated if they are upregulated at all). This
would be reasonable since really there is no foreign microbial or 'living' agent that needs
to be protected against or neutralized.
Any injury that may potentially occur and that may cause free radical generation should
be contained by factors that neutralize these possible free radicals-one might be
NADPH. Glucose 6-phosphate dehydrogenase is the first enzyme in the pentose
phosphate pathway and controls the production of NADPH (a "...reductant essential in
many biosynthetic pathways" pg 551 [89]). Only one probeset was obtained on a search
for G6PD. Its t squared statistic value is 0.7-not very high, but still positive.
Liu et al [90] mention that lactate dehydrogenase is not a very sensitive marker for cell
injury by stretch. It was decided nevertheless to see if lactate dehydrogenase may
possibly be upregulated in our system. Surprisingly, a lactate dehydrogenase geneset
went straight to the bottom (of the UPregulated analysis) with an ES score of 0.9 (the
highest ES score was OXPHOSHG-U133Aprobes with a score of 446.
Brickson et al [91] performed "a standardized single stretch injury ... [by subjecting the
rabbits to acute stretch] ... on the tibialis anterior (TA) muscle of 36 male New Zealand
white rabbits ... [with] contralateral control limbs ... [undergoing] a sham surgery". Their
results show an increase in the production of superoxide dismutase and Xanthine
oxidase. [91]
Thus SOD and XO genesets were created and the ES scores obtained were 100 and 74
out of 177 genesets (not very high)-their ranks were 81 and 104 respectively. This result
isn't very surprising, since we saw earlier that SOD modulates the conversion of NO- to
NO, and NO itself is downregulated. Thus, we need to find other markers of stretch
injury (if indeed there is "injury" in our system). Collagen XII gene expression was found
to be increased in an ex vivo model of rat bladder stretch injury[92].
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A search on NetAffx yielded only one probeset for "collagen XII". Although searching
for one probeset may be prone to noise, its t statistic squared value is still useful because
it is extracted from 8 paired time points and also because it still gives us some idea of its
up or down regulation. We found that this probeset was slightly downregulated with a t
squared statistic of -1 approximately.
Thus, at least the genes (or genesets) that we've looked at, seem to show that there is
little cell injury. However, heme oxygenase is being heavily upregulated, and therefore
there must be some damage that this enzyme is protecting against. For example,
Otterbein et al [93] show that "Exogenous administration of heme oxygenase- 1 by gene
transfer provides protection against hyperoxia-induced lung injury". This paper
interestingly also shows that in this system (where HO-1 gene was overexpressed in the
rat lung through gene transfer), HO-1 doesn't upregulate superoxide dismutase or L-
ferritin or H-ferritin (this is exactly what we had predicted earlier, since in our
system NO is suppressed and SOD upregulates NO).
Before we deduce the pathway that may be at work, let's see what heme oxygenase does
downstream.
Heme oxygenase downstream action
The following pathway shows that heme oxygenase modulates the transformation of
heme to CO, biliverdin IXa (which is then converted to bilirubin), and iron [93], [94]
Hemne oxygenase Co
heme Biliverdin bilirubin
IX
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The pathway that may be at work
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Items in red are downregulated/present in small amounts
Items in green are either upregulated or events that are known to happen in our system
] Items in light green are possible guesses on events or upregulated genes
Items shown in grey are events that don't happen
'I
w
For comparison, the hypoxia gene set is given in the previous section (the items in our
pathway are in bold and larger font).
Caveats in drawing the above pathway conclusion
A caveat that should be kept in mind is that gene set enrichment analysis damps the
effects of noise by looking at the 'movement' of a group of genes in a system rather than
the 'movement' of one gene itself. Thus, even though it is reasonable to conclude that
hypoxia itself is in general the most regulated, drawing conclusions about each gene in
the set may lead to erroneous conclusions. These conclusions may especially be the more
erroneous if we try to draw comparisons between the regulations of genes both of which
may move in the same direction but show very little difference in the t statistic squared
scores.
Another caveat that must be given is that the t scores themselves while not small aren't
the largest seen in the system. It is their aggregate value as seen through the Kolmogorov
Smirnov statistic that lends the GSEA its strength and usefulness.
One mitigating and helpful factor is that in our analysis we had eight time points that
were paired, and thus in essence the t statistic itself had a basis in 'strength in numbers' in
predicting the 'movement' of genes (and not just genesets). This gives us some
confidence in the strength of the results obtained.
To gain a further understanding of the system, the top 10 genes from each of the three
analyses (combined, up and down regulated) were obtained.
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The top 10 genes in the analysis were found (combined, the upregulated, and the
downregulated).
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Next, the bootstrap technique of permutation testing (which uses replacement as the
permutations are conducted) was performed to see if indeed as Good mentions [58], both
the bootstrap and the permutation test give us comparable results.
Bootstrap analysis
The results of the bootstrap analysis were very similar to the P test of the permutation
test. Two iteration results are given below:
Bootstrap results 1st iteration
P
geneset value
c2_U133_probes.txt 0.075
c7_U133_probes.txt 0.053
OXPHOSHG-U133Aprobes.txt 0.047
c18_U133_probes.txt 0.035
MAP001 00_Sterolbiosynthesis.txt 0.023
c6_U133_probes.txt 0.023
c1lU133_probes.txt 0.019
MAP00900_Terpenoid-biosynthesis.txt 0.017
MAP00970_Aminoacyl-tRNA biosynthesis.txt 0.017
MAP00280_Valineleucineandisoleucinedegradation.txt 0.016
cluster15_LPS_mouse_urinary.txt 0.016
c3_U133_probes.txt 0.015
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c5_U133_probes.txt 0.015
c33U 1 33_probes.txt 0.014
responsetomechanicalstimulus.txt 0.013
cO_U1 33_probes.txt 0.012
c27U 1 33probes.txt 0.012
c9_U133_probes.txt 0.012
MAP00430_Taurineand-hypotaurinemetabolism.txt 0.011
c25U 1 33probes.txt 0.011
Bootstrap results 2nd iteration
geneset P value
C7_U133_probes.txt 0.068
c2_U 1 33probes.txt 0.052
OXPHOSHG-U1 33Aprobes.txt 0.05
c1 8U1 33_probes.txt 0.032
c6_U1 33_probes.txt 0.025
c24U 1 33_probes.txt 0.023
MAPOO1 00_Sterol-biosynthesis.txt 0.02
MAP00970_Aminoacyl-tRNA-biosynthesis.txt 0.02
cl_U133_probes.txt 0.018
c33U 1 33_probes.txt 0.016
c1 5U1 33_probes.txt 0.015
cluster1OLPSmouseurinary.txt 0.015
responsejto-mechanicalstimulus.txt 0.015
MAP00900_Terpenoid-biosynthesis.txt 0.014
c5_U133_probes.txt 0.014
c25U 1 33_probes.txt 0.012
c35U 1 33_probes.txt 0.012
cO_U1 33_probes.txt 0.011
cluster15_LPSmouseurinary.txt 0.011
inflammatory.txt 0.011
For comparison, here are the results of the Permutation test (only one iteration shown):
Permutation test
geneset P value
c7_U133_probes.txt 0.068
c2_U133_probes.txt 0.062
OXPHOSHG-U1 33A-probes.txt 0.033
c18_U133_probes.txt 0.032
MAP001 00_Sterol-biosynthesis.txt 0.022
MAP00900_Terpenoid-biosynthesis.txt 0.019
c3_U1 33_probes.txt 0.018
humanmitoDB_6_2002_HG-U133A-probes.txt 0.018
clU133_probes.txt 0.016
c27U1 33-probes.txt 0.016
MAP00562_Inositol_phosphate-metabolism.txt 0.014
TCAHG-U1 33A-probes.txt 0.014
cO_U133_probes.txt 0.014
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c24_U 1 33_probes.txt 0.014
c9_U1 33_probes.txt 0.014
responsetomechanicalstimulus.txt 0.014
c1 5U 1 33_probes.txt 0.013
c23_U133_probes.txt 0.013
c5_U1 33_probes.txt 0.013
MAP00561_Glycerolipid-metabolism.txt 0.012
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Singular value decomposition
Any n x p matrix can be decomposed into a left orthonormal n x p matrix, a square p x p
diagonal matrix of eigenvalues, and a right orthonormal p x p matrix called the
'eigenassay' [95]. The left eigenvector or eigengene coefficients tell us about the
important variances in the genes (however since our rank has to be either 8 or lower
than 8, it would seem that we can at most have only 8 significant variances down
each column).
Obtaining the SVD on the dataset.
We have 8 time points control and 8 time points stretched. First we take the ratio of
stretch to control to obtain the fold change in the expression profiles. Now we have the
starting data matrix on which we'll perform the SVD.
Save the data as a text file (this can be done in excel). Each row of the text file contains
the 8 time point normalized values for a single gene. In R, we save this file in the
C:\Program Files\R\rw2010 directory (or whatever directory R reads from). To load this
file into a matrix Z, we do the following:
Z<-matrix(scan("ratio.txt"),nrow=31099,byrow=T)
The above will load the file 'ratio.txt' which into a matrix with 31099 rows (that's the
number of genes we're scanning in-technically 31099 is really the number of probesets
that we're scanning in, not the number of genes).
To perform the SVD on the Z matrix, type:
decomposition<- svd(Z)
The results of the svd are then stored in the variable 'decomposition'
To see the U, S, and V matrices of the SVD, we can type
decomposition$u
decomposition$v
decomposition$d
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To obtain each of the eight left eigenvectors (with 31099 components each), we can
essentially read each column of the U matrix (given by decomposition$u) into a new
vector. This is done by typing,
u 1 <-decomposition$u[ , 1]
Note that there is a space before the comma in the square brackets. This will load the first
column into the vector u 1. u2 would be given by
U2<-decomposition$u[ ,2]
and so on.
Now we load each of these eight vectors into eight separate text files by typing,
write(u l,ncol= 1,"u L.txt")
In the above command, note that we need to specify ncol=1. Otherwise, 'R' will load the
data into more than one column.
Next we created a two column file (say 'expression 1.txt') with indices starting at 0 in the
first column and the coefficients in the second column (the absolute values of the
coefficients are used since the variation is captured in the absolute values-the sign being
unimportant)s. We next ran the GSEA on this set.
Results
The top ten genesets for each left eigenvector are given below:
LEV=left eigenvector
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LEV1
response tomechanicalstimulus.txt 1
MAP00361-gammaHexachlorocyclohexane-degradation.txt 6
c14_U133_probes.txt 1
MAP00430_Taurineand-hypotaurinemetabolism.txt 6
HumFbSerumEarlyTF.txt 2
MAP00480_Glutathionemetabolism.txt 3
MAPOOl 50_Androgen-and-estrogenmetabolism.txt 4
c26U 1 33_probes.txt 1
MAP00940_Flavonoidsstibeneandignin-biosynthesis.txt 6
OXPHOSHG-U1 33A-probes.txt 1
LEV2
c24U1 33_probes.txt 3
MAP00940_Flavonoidsstilbeneandignin-biosynthesis.txt 6
clusteri 1_LPSmouseurinary.txt 3
c29U1 33_probes.txt 1
MAP00430Taurineand-hypotaurinemetabolism.txt 6
MAP00361_gammaHexachlorocyclohexane-degradation.txt 6
c2_U 1 33_probes.txt 1
clusteri5_LPSmouseurinary.txt 2
MAPOO602_Blood-group-glycolipid-biosynthesisneolactseries.txt 1
MAP00040_Pentoseand-glucuronateinterconversions.txt 3
LEV3
MAP001 50_Androgen-andestrogenmetabolism.txt 4
MAP00361_gammaHexachlorocyclohexane-degradation.txt 6
c31_U133_probes.txt 1
MAP00940_Flavonoidsstilbeneandignin-biosynthesis.txt 6
MAP00140_C21_Steroidhormonemetabolism.txt 2
MAP00040_Pentoseand-glucuronateinterconversions.txt 3
c24_U133_probes.txt 3
perception-of-pain-sensorytransductuonofmechanicalstimulus.txt 1
sensory-perception-of-mechanicalstimulus.txt 1
cluster15_LPSmouseurinary.txt 2
LEV4
ECMconstituentconferring-elasticity.txt 1
ECMstructuralconstituentconferring-compressionresistance.txt 1
FAHG-U1 33A-probes.txt 1
GLUCOHG-U1 33A-probes.txt 1
GLYCOGENHG-133Aprobes.txt 1
GLYCOLHG-Ui 33A-probes.txt 2
GO_0005739_HG-U133A-probes.txt 1
HumFbSerumChol_Biosyn.txt 1
HumFbSerumCoagHemo.txt 2
HumFbSerumEarlyTF.txt 2
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LEV5
MAP00051_Fructoseandmannosemetabolism.txt 2
c24U 1 33_probes.txt 3
MAP00430_Taurineand-hypotaurinemetabolism.txt 6
HumFbSerumCoagHemo.txt 2
MAP00361_gammaHexachlorocyclohexane-degradation.txt 6
clusteri 1 _LPSmouseurinary.txt 3
MAP00040_Pentoseand-glucuronateinterconversions.txt 3
MAP00480_Glutathionemetabolism.txt 3
GLYCOLHG-U1 33A-probes.txt 2
c22U1 33_probes.txt 2
LEV6
MAP00430_Taurineand-hypotaurinemetabolism.txt 6
MAP00251_Glutamatemetabolism.txt 1
MAP00361_gammaHexachlorocyclohexane-degradation.txt 6
MAP00740_Riboflavinmetabolism.txt 1
MAP00512_OGlycans-biosynthesis.txt 2
MAP00960_AlkaloidbiosynthesisI I.txt 1
MAP00940_Flavonoids_stilbeneandignin-biosynthesis.txt 6
MAP00051_Fructoseandmannosemetabolism.txt 2
c22U 1 33_probes.txt 2
clusteri 1_LPSmouseurinary.txt 3
LEV7
MAP00361_gammaHexachlorocyclohexane-degradation.txt 6
MAP00940_Flavonodsstilbeneandjlignin-biosynthesis.txt 6
cluster4_LPSmouseurinary.txt 1
MAP001 50_Androgen-and-estrogenmetabolism.txt 4
MAP00512_QGlycans-biosynthesis.txt 2
MAP00430_Taurineand-hypotaurinemetabolism.txt 6
MAP00140_C21 Steroid hormone metabolism.txt 2
MAP00533_Keratansulfate-biosynthesis.txt 1
inflammatory.txt 1
MAP00472_DArginine-and_D_ornithinemetabolism.txt 2
LEV8
clusterl4_LPSmouseurinary.txt 1
inflammatory-mechanical.txt 1
MAP00430_Taurineand-hypotaurinemetabolism.txt 6
MAP00940_Flavonodsstilbeneandignin-biosynthesis.txt 6
MAP001 50_Androgen-and estrogen-metabolism.txt 4
cluster2_LPSmouseurinary.txt 1
MAP00580_Phospholipid-degradation.txt 1
MAP0071OCarbon_fixation.txt 1
MAP00472_DArginine-and_D_ornithinemetabolism.txt 2
MAP00480_Glutathionemetabolism.txt 3
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If the above analysis has validity, it does show as expected that 'response to mechanical
stimulus' is the most important gene set as far as time series are concerned. This analysis
has thus extracted the most important geneset from one time point to another. The
analysis we did where we ordered the genes with the T statistic squared really looked at
the difference between stretch and control. Here we are no longer saying that 'response to
mechanical stimulus' differentiates the stretch versus the control conditions. We are
saying that this geneset is important in going from one time point to another (it may
however also have importance in looking at stretch versus control-as it should, but that
information isn't obtainable from the SVD analysis. We have to do the T statistic GSEA
to see that separately.
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Chapter 5
Finite element analysis using Biphasic wound model
To replicate the wound more faithfully, and also to address commentary that
accompanied our solid finite element publication, a biphasic finite element model was
constructed.
The Finite element model
As before, ADINA (ADINA inc, Watertown MA) was used to conduct the analysis. A
2D model was created using the FSI (or fluid structure interfact) formulation in ADINA.
4 node elements were used (9 node elements were unsuccessful in our model). To use the
FSI formulation, two different models have to be created, one model in the ADINA
module (which pertains to solid conditions) and one in the ADINA-F (F referring to
fluid) module. Each module has the FSI condition on the menu applied (or checked).
Let's look at the details of the model building step in each module
ADINA (solid)
1) Under control-degrees of freedom, leave the checks only on the Y-translation and Z-
translation options
2) Next control 4 fluid structure interaction 4 check both 'fluid structure interaction'
and 'includes porous coupling'
3) Geometry 4 points + enter the points (Xl stands for the 'X' coordinate. In the 2D
system, we really only use the X2 and X3 coordinates or the Y and Z coordinates.
Therefore for our analysis, we leave the Xl coordinate blank. Also, leaving the
'system'-which stands for coordinate system blank implies that we use the default
'zero' coordinate system.
4) Geometry + using the points we then create 4 surfaces
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5) The next picture shows our model with the coordinate point locations for the solid
model (remember, we're creating only the solid section for now). Also, as opposed to
the solid only analysis where we actually modeled the struts, in this case, we're only
modeling the intra-strut space.
(0,0.0005) Line 2 (0.0012,0.0005)
Line 3 Line 4
(0,0) Line 1 (0.0012,0)
6) Model 4 porous media properties are initially greyed out, but this item needs to be
set (even though the values we specify don't seem to make a difference). We first
need to specify the element group and then specify 'porous media properties'. First
however, let's specify the materials, boundary conditions and loads.
7) Model + material - elastic + isotropic - add (new material) + enter the values of
the Young's modulus, the Poisson's ratio, and the density (although the density isn't
really important since this is not a dynamic analysis (where transient terms are
important).
8) Model + Boundary conditions - FSI boundary + add (new FSI) 4 apply to line at
bottom (shown as line 1 above). Now, it is important to note that each non-continuous
FSI condition has to be applied with a new FSI number. Therefore, we have to click
on 'add' again and then apply another FSI boundary on line 2 (above).
9) Model - Boundary conditions - define fixity 4 add (call this fixity yfixed) 4
Fixed degrees of freedom 4 check the y translation box (leave the z translation
unchecked). Apply this fixity next to lines 3 and 4 above.
10) (Applying the above created fixity) Model + Boundary conditions 4 Apply fixity -
Apply to: Lines, (choose lines 3 and 4 above), and under 'apply fixity' column,
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choose from the drop down option (this option becomes visible when we click on the
rows under this column) yfixed.
11) Model 4 Loading + Apply + Load type: displacement, Apply to (leave as point),
Load number: click 'define' -+ Add 4 Prescribed values of translation 4 X:O, Y:0,
Z:O (we could have also defined fixity rather than zero displacement loading to get
the same result on this loading/boundary condition).
12) Now, we go back and apply 'porous media property'-this option is no longer grey;
Model 4 materials - porous media property + don't change anything, click OK.
13) Meshing 4 element groups 4 add (new element group) - type: 2D solid, Default
material (leave as 1), element sub-type: plane strain, element option: porous media.
14) Meshing 4 mesh density 4 surface 4 Number of subdivisions: u: 20, v: 10 (we may
have to swap these depending on which way the surface ended up being defined. We
essentially want the larger number of divisions on lines 1 and 2 above).
15) Meshing 4 create mesh - surface 4 element group (leave this as 1), Nodal
specification: Nodes per element: change to 4 from 9. Surface: enter 1. Click OK.
16) Solution 4 Data File/Run 4 uncheck the 'Run ADINA' option (because we only
want to save the data file rather than running ADINA-we'll do the same under the
fluid option, and then we'll run the two files we generate together under FSI).
17) After running the data file creation above, click on SAVE to save the file. Then go to
File 4 new. We're ready for the fluid analysis.
Next we look at ADINA-F model creation.
ADINA-F model creation
1) Choose ADINA-F module, click on FSI
2) Model 4 flow assumptions 4 Flow dimension: 2D, uncheck 'includes heat transfer',
'Fluid Structure interaction': check FSI, check 'includes porous coupling'.
3) We create the fluid model. Geometry - points + enter the points as shown in the
pictorial below:
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(0, 0.001) (0.0012, 0.001)
Surface 2 0.5 mm
(0, 0.0005) Line 2 (0.0012, 0.0005)
Surface 1
0.5 mm
(0,0) Line 1 (0.0012,0)
Surface 3
0.5 mm
(0, -0.0005) (0.0012, -0.0005)
4) Now we'll define two different fluid materials, the material in the center being porous
fluid, and the material on either side being a regular 'non-porous' fluid. First, let's
create the surfaces using the vertices we listed above.
5) Model - materials - constant -- add (this will be listed or added as material 1) -
viscosity: 0.015, density: 1000
6) Model + materials - porous + add (this will be listed or added as material 2) 4
fluid: density: 1000, permeability: X: 10e-16, Y: lOe-16, Z: lOe-16, Porosity: 0.5,
viscosity: 0.015.
7) Model - Usual Boundary conditions/Loads 4 Zero values - add - call this
'noYvelocity' + degrees of freedom with zero values - check 'Y-velocity' (we will
apply this 'zero value' boundary condition to lines.
8) Model - Usual Boundary conditions/Loads - apply zero values 4 apply to: lines,
under 'line #' pick the lines, under zero values (when we click in this column the drop
down list with all zero value options becomes available) pick noYvelocity for each
line number. OK
9) Model - special boundary conditions + add - type: fluid-structure interface, slip
condition: no, apply to: line 1. NOW click ADD and then repeat on line 2 in the
figure above (same reasoning as before-if we have two discontinuous FSI
boundaries, we need to create separate FSI interaction numbers).
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10) Model - Usual Boundary conditions/Loads - apply - Load type: Normal Traction,
apply to: line, load number 4 define - add + enter magnitude (say 10000), choose
line at bottom.
11) Meshing + element group 4 material 1 -> element sub-type: planar, 2D fluid
(default)
12) Meshing -> element group -> material 2 -> element sub-type: planar, 2D fluid
(default)
13) Meshing 4 mesh density 4 4 (down), 5 (across) (all surfaces)
14) Meshing - mesh surfaces -> nodes per element: 3, element group: 2 (porous),
surface (porous) 1. Then add + repeat for element group 1 (non porous) and apply to
surfaces 2 and 3.
15) Save as data file
16) Run the FSI by going to Solution + Launch ADINA FSI - use ctrl to choose the
two files 4 OK
Results
Average surface strain versus E
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Average surface strain versus Pressure
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Viscosity and permeability were also changed, but they showed very little variation in
average strains (however, they did show changes in velocity). Further, the model became
unstable over values of Poisson's ratio that were lower than 0.47. Thus, the values of
Poisson's ratio that were obtained were over too small a variation.
Next, let's look at variation of strain over the length of the pore
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% surface strain versus pore length
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Next we look at some of these parameters for the solid model to see if we have similar
strains or different stains (we obtain similar strains).
Surface strain versus pressure in solid model
strain versus P solid model
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Surface strain versus pore size in solid model
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strain versus pore size
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Conclusions
We see that the strains are very similar. Thus, the solid approximation is quite
appropriate.
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Glossary
Isotropic/anisotropic Assumes the stiffness of a material is the same along any axis. A
biologicexample of an isotropic material is fat. In contrast, many biologic materials are
anisotropic:they are very strong along one axis and weak perpendicular to that axis. For
example, a tendonis very stiff along its longitudinal axis and much less stiff across its
transverse axis.
Linear Assumes data can be fit to an equation of a line. For most biologic materials such
as skin, the relationship between stress andstrain is nonlinear and exponential in nature
over large strains. To simplify the model, a linear stress-strain relationship is assumed
over small displacements.
Pore volume fraction (Vf) Proportion of sponge occupied by air; pore diameter divided
by the pore diameter plus strut thickness.
Fold change Ratio of expression values (for example stretch to control).
Morphogenesis (cell biology) The process of shape formation: the processes that are
responsible for producing the complex shapes of adults from the simple ball of cells that
derives from division of the fertilized egg (From online medical dictionary).
Suture Closing a wound with suitable biocompatible 'thread'. In general, a suture can be
applied to non biological tissue (as when we 'suture' the force-producing rubber band to
the latex that is attached to the rat ear).
Biological replicate/technical replicate A biological replicate refers to multiple
biological samples, while a technical replicate refers to multiple microarray runs.
Granulation: One of the small, red, grainlike prominences which form on a raw surface
(that of wounds or ulcers), and are the efficient agents in the process of healing. The act
or process of the formation of such prominences.
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Keratinocyte: <pathology> skin cell, of the keratinized layer of epidermis: its
characteristic intermediate filament protein is cytokeratin.
Focal adhesions: <cell biology> Areas of close apposition and thus presumably
anchorage points, of the plasma membrane of a fibroblast (for example) to the substratum
over which it is moving; Usually Im x 0.2 m [sic-online medical dictionary] with the
long axis parallel to the direction of movement, always associated with a cytoplasmic
microfilament bundle that is attached via several proteins to the plasma membrane at an
area of high protein concentration (this is noticeably electron dense in electron
micrographs). Focal adhesions tend to be characteristic of slow moving cells.
Microfilament: <cell biology> Cytoplasmic filament of F actin (5-7nm) which function
in structure and movement in eukaryotic cells. They may be laterally associated with
other proteins (tropomyosin, alpha actinin) in some cases and may be anchored to the
membrane. Microfilaments are conspicuous in adherens junctions.
Microtubule: <cell biology> Cytoplasmic tubule, 25nm outside diameter with a 5nm
thick wall. Made of tubulin heterodimers packed in a three start helix (or of 13
protofilaments looked at another way) and associated with various other proteins (MAPs,
dynein, kinesin). Microtubules of the ciliary axoneme are more permanent than
cytoplasmic and spindle microtubules. (online medical dictionary)
"Microtubules are components of all eukaryotic cells. They participate in a range
of motion processes, such as:
" the movements of flagella and cilia,
" the movements of chromosomes during meiosis and mitosis [being part of the
spindle] and
" the transport of granules and vesicles within the cells that effects cell wall
formation, shape and specialization of the cells" (15).
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Paracrine: <endocrinology> Form of signalling in which the target cell is close to the
signal releasing cell. Neurotransmitters and neurohormones are usually considered to fall
into this category.
Glycoproteins: Conjugated proteins containing one or more covalently linked
carbohydrate residues. While technically describing conjugates in which the carbohydrate
is less than 4 per cent by weight, the term is often used generically to include the
mucoproteins and proteoglycans (19).
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Proteoglycans: Glycoproteins which have a very high polysaccharide content (on-line
medical dictionary-(19)).
Glycosaminoglycans (Stryer 5th ed-(18)): Glycosaminoglycans Are Anionic
Polysaccharide Chains Made of Repeating Disaccharide Units
(http://www.ncbi.nlm.nih.gov/entrez/guery.fcgi?cmd=Search&db=books&doptcmdl=Gen
BookHL&term=proteoglycans+AND+stryer%5Bbook%5D+AND+215807%5Buid%5D
&rid=stryer.section.1517#1526) - Stryer 5th ed online.
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Figure: Repeating units in different glycosaminoglycans
The glycan of a proteoglycan is a glycosaminoglycan, but a glycosaminoglycan can exist
separately from a protein. Thus, a GAG is either just a GAG or is part of a PG. However,
in cartilage PGs can be linked to a GAG - hyaluronan (20).
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Appendix
P value finder with T test sorting
#!/usr/bin/perl -w
use strict;
#this code computes the P value for a given list of genesets. Our final result from
#this code is a table of P values versus geneset names. We will first obtain ES for each
geneset
#in a particular permutation. This will be stored in a 2D array that has geneset in first
column
#and ES in second column. This list will then be sorted largest to smallest to give us the
geneset
#with maxES for that permutation. This geneset name will be pushed into an array called
count. We
#will finally count the values of each geneset in this array. The inverse of each of these
will
#be the P values for each of these genesets. We will write a subroutine within the 1000
for loop
#that will return just one scalar argument (a string) that will be the MES geneset in each
iteration
#of the permute.
#first the 1000 loop
my @datal;
my @new;
my @count;
my @n;
my $k;
125
my @newl;
for(my $asub=0; $asub<=999; $asub++)
print "loop $asub \n";
push (@count, &ESfinder);
print "\n \n \n";
print "$count[$asub] \n";
print "\n \n \n";
} # end of global permute
#load geneset filenames into datal array
my $gsetfiles = "gsetfiles.txt";
open(FH,"<$gsetfiles") or die("can't open input file $gsetfiles.txt: $!\n");
while (my $line=<FH>){
chomp($line);
push(@datal, $line);
}
close FH;
#count the number of times each geneset occurs in array count.
#now we count
for($k=0;$k<=$#datal;$k++){
$new[$k]=0;
for ($a=0;$a<=999;$a++){ #here we've used 1000, since we're only getting one
max value per permute
if($datal[$k] eq $count[$a]){
$new[$k]=$new[$k]+l;
# print "$new[$k] \n";
}
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II
#finally output results to a file (the P value next to gene name)
for(my $a=O;$a<=$#datal;$a++){
$new I[$a]=$new[$a]/1000;
# print "$allES[$a][0] \t $n[$a] \n";
# print "$al1ES[$a][O] \t $new[$a] \n";
I
#print max enrichment score
for (my $b=O;$b<=$#datal;$b++){
print "geneset $data I[$b] \t has P value \t $new I[$b] \t & \t $new[$b] \n";
I
#check count if all there
# for(my $check=O;$check<=999;$check++){
# print "$count[$check] \t $check \n";
# }
#print results to a file
open OUTPUTFILE, ">outputfile.txt";
for (my $a=O;$a<=$#datal;$a++){
print OUTPUTFILE "$datal [$a] \t has P value \t $newl [$a] \t & \t $new[$a] \n";
I
close OUTPUTFILE;
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# now define the subroutine
sub ESfinder {
#load expression 1.txt into a matrix with 3 columns
my @data;
my @parsed;
my $sum;
my @pES;
my @sort-pES;
my $mES;
my $s;
my $i;
my @psort-new;
my @datal;
my $gsetfiles;
#We'll have to modify the expression 1 text file to have all the eight time points
my $expressionl="expressionl .txt";
open(EXPRESSION 1,$expression 1) or die("can't open input file $expressionl: $!\n");
while(<EXPRESSION1>){
chomp($_);
push(@data, $_);
}
close EXPRESSION 1;
for (my $i=O; $i<=$#data; $i++) {
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push(@parsed, [split(At/, $data[$i])])
I
print "number in permute \n";
#save $#data in $datalength and kill @data
my $datalength=$#data;
@data=();
#our code will be different from here on down
#generate 8 random numbers corresponding to each column in the stretch system
#generate an array with first column being integers 9 through 16
my @StretchSorter;
my @StretchSorted;
for (my $a=O;$a<=7; $a++){
$StretchSorter[$a] [0]=$a+9;
$StretchSorter[$a] [1 ]=randO;
}
# for (my $a=O;$a<=7; $a++){
# print "$StretchSorter[$a] [0] \t $StretchSorter[$a][1] \n";
#1
print "\n \n";
#sort StretchSorter
@ Stretch_Sorted=sort { $b->[ 1] <=> $a->[ 1] } @ StretchSorter;
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# for (my $a=0;$a<=7; $a++){
# print "$StretchSorted[$a][0] \t $StretchSorted[$a][1] \n";
# }
# --------------------------------------------------------------
#define the swap algorithm
#start with a random number for each column in the control set
#if number greater than 0.5 swap otherwise not swap
#this defines whether we swap or not
my @ControlTracker;
my @Tsquare;
for(my $a=O;$a<=7;$a++){
my $random=randO;
if ($random > 0.5){
$ControlTracker[$a]=$StretchSorted[$a] [0];
$StretchSorted[$a] [0]=$a+l;
}
else {$ControlTracker[$a]=$a+1;}
}
#permute the matrix
for(my $a=0;$a<=$datalength;$a++){
my $Xsum=0;
my $Xmean=0;
my $Ysum=0;
my $Ymean=0;
# the next loop computes the sum of each group
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for(my $b=O;$b<=7;$b++) {
$Xsum+=$parsed[$a] [$ControlTracker[$b]];
$Ysum+=$parsed[$a] [$StretchSorted[$b] [0]];
}
#now we compute the means
$Xmean=($Xsum/8);
$Ymean=($Ysum/8);
#calculate the t statistic denominator summation
##first make an intermediate variable of Ybar-Xbar
my $Sumhelper=$Ymean-$Xmean;
#now the summation
my $Denom-sum=O;
my $Denom-sum-square=O;
for(my $b=O;$b<=7;$b++) {
$Denom-sum=($Sumhelper+$parsed[$a][$ControlTracker[$b]]-
$parsed[$a] [$StretchSorted[$b] [0]]);
$Denomsumsquare+=($Denom sum*$Denom-sum);
}
$Tsquare[$a][0]=$a;
$Tsquare[$a] [1 ]=($Sumhelper*$Sumhelper)*(8 *7)/($Denom sumsquare);
#close the a loop
}
@parsed=();
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#sort
@psort new=sort{$b->[1] <=> $a->[1] } @Tsquare;
print "array sorted \n";
# for (my $newloop=O; $newloop<=$datalength; $newloop++){
# print "$parsed[$newloop][3] \t $parsed [$newloop][2] \t $parsed[$newloop][1]
\n";
#}
#next do a for loop from 1 to number of genesets. This can be found by loading the file
called
#gsetfiles.txt. This will load all the genesets into array datal. Next we will load each
geneset file
#from datal into vector called geneset and find the running sum. A sorting of this will
give ES.
#This ES will be 'pushed' into a 2D array with first column gset name and the second the
ES. At
#the end of the for loop the array geneset will be set to () and then undef.
#so first load genesetfile into array datal.
$gsetfiles = "gsetfiles.txt";
open(FH,"<$gsetfiles") or die("can't open input file $gsetfiles.txt: $!\n");
while (my $line=<FH>){
chomp($line);
push(@datal, $line);
I
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close FH;
print "genesetfile loaded \n";
#now loop from 0 to number of genesets. In each loop load the i'th file and then compute
the
#running sum and then sort this file to obtain the ES for this geneset. push this number
into a
#2D array with the first column being genesetname and the second the ES
my @sumArray;
my @sumArraySort;
for($i=0; $i<=$#datal; $i++){
my @gsetarray;
print "$i \n";
open(FH1, "<$datal[$i]");
while(<FH 1>) {
chomp($_);
push(@ gsetarray,$_);
}
#remember now that our gsetfiles are all data entries long
#now find the running sum of @gsetarray by referencing the psortnew array
indices
for($s=0;$s<=$#gsetarray;$s++){
# print "$s \n";
if ($s==O){
$sum=$gsetarray[$psort-new[0] [0]];
I
else {
$sum=$gsetarray[$psort-new[$s] [0]]+$sum;
I
$sumArray[$s]=$sum;
}
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@sumArraySort = sort { $b <=> $a } @sumArray;
$pES[$i][0] = $datal[$i];
$pES[$i][1] = $sumArraySort[O];
$sum=O;
@ gsetarray=();
@sumArray=();
@sumArraySort=();
print "sum computed \n";
#now we sort @pES by the column number 1 (with ES scores). We pull off the first entry
in
#column 0. This is the gsetname that is sent back from the subroutine.
@sort_pES=sort{ $b->[ 1] <=> $a->[ 1]} @pES;
$mES=$sortpES [0] [0];
#print "$mES \n";
#print "$sort_pES[0][0] \n";
#print "$pES[0][0] \n";
print "$mES \n";
return $mES;
} # end of subroutine
# #good way to check
# #if ($a % 5000 == 0) { print "$a...\n";}
# if (!defined($value)) { print "$value is undefined";}
# if it's a show stopper, you can use die("error message"); instead
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Appendix
Creating genesets correctly formatted (see text in thesis for what this means)
The following code will create different gene set files with the Kolmogorov statistic on
each line corresponding to its gene (see main body of thesis for explanation)
#!/usr/bin/perl
#this program requires the following input files:
#gsetfiles.txt (this file has list of all gsetfiles--eg. gsetl.txt, gset2.txt etc one on each line
#the gset.txt files should only have gene names not squared values
#expression.txt (just one time point expression set)
$expression="expression.txt";
open(EXPRESSION,$expression) or die("can't open input file $expression: $!\n");
while(<EXPRESSION>){
chomp($_);
push(@data, $_);
}
close EXPRESSION;
for (my $i=O; $i<=$#data; $i++) {
push(@parsed, [split(At/, $data[$i])])
I
print "LOOPS 0000000000 \n";
$gsetfiles = "gsetfiles.txt";
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open(FH,"<$gsetfiles") or die("can't open input file $gsetfiles.txt: $!\n");
while (my $line=<FH>){
chomp($line);
push(@datal, $line);
}
close FH;
for($i=O; $i<=$#datal; $i++){
open(FHl, "<$datal[$i]");
while(<FH 1>) {
chomp($_);
push(@ gsetarray,$_);
}
foreach $j (@gsetarray) {
push(@tempgsetarray, $j) unless ($seen{$j }++);
I
@gsetarray = @tempgsetarray;
@tempgsetarray=();
%seen=();
$length[$i]=$#gsetarray;
for($b=O;$b<=$#gsetarray;$b++){
$array[$i][$b+1]=$gsetarray[$b];
I
@ gsetarray=();
}
for($a=O;$a<=$#data;$a++){
$ExampleGlobal[$a]=$parsed[$a] [0];
I
for ($a=0;$a<=$#datal;$a++){
for($b=1;$b<=$length[$a]+1;$b++)I
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$ExampleSubset[$b- 1 ]=$array[$a] [$b];
}
my %ExampleGlobalHash;
foreach my $i (0..$#ExampleGlobal) {
if (!defined($ExampleGlobalHash{$ExampleGlobal[$i]})) {
$ExampleGlobalHash{ $ExampleGlobal[$i] =$i;
}
}
foreach my $j (0..$#ExampleSubset) {
if (defined($ExampleGlobalHash{ $ExampleSubset[$j] })) {
$index=$ExampleGlobalHash { $ExampleSubset[$j] };
$parsed[$index][$a+4]=1;
}
}
@ExampleSubset=();
}
print "loop 22222222222 \n";
#-------------------------end of geneset loading----------
#------------add zeroes to the rest of the matrix---------
for($a=0;$a<=$#data;$a++) {
for($b=4;$b<=$#datal +4;$b++){
if($parsed[$a] [$b]!=1) {
$parsed[$a] [$b]=0
i
}
}
#-----the above is an exercise in futility but makes the code run with the previous code
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#create the difference column
for($c=O; $c<=$#data; $c++){
$parsed[$c] [3]=$parsed[$c] [2] -$parsed[$c] [1];
I
#find the statistics
print "LOOPS 3333333333 \n";
for($aaaaa=O;$aaaaa<=$#datal;$aaaaa++){
for($bbbbb=O;$bbbbb<=$#data;$bbbbb++){
$XNG=-sqrt(($length[$aaaaa]+1)/($#data-$length[$aaaaa]));
$XG=sqrt(($#data-$length[$aaaaa])/($length[$aaaaa]+1));
if ($parsed[$bbbbb] [$aaaaa+4] == 1){
$parsed [$bbbbb] [4+$aaaaa]=$XG;
}
else {
$parsed[$bbbbb] [4+$aaaaa]=$XNG;
}
}
#print gset entries to different gset files
#we must remember that @datal has the list of all genenames indexed from 0 to $#datal
# ------------------------------------------------------------------------------------
for($i=0; $i<=$#datal; $i++){
open(FH2, ">$data I[$i]");
for ($a=O;$a<=$#data;$a++){
if ($a != 0){print FH2 "\n";}
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print FH2 "$parsed[$a][4+$i]";
}
close FH2;
}
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Appendix
Combined up and down regulated ES scores and P values for 3 iterations
Gene Set
hypoxia.txt
responsetomechanicalstimulus.txt
c3_U1 33_probes.txt
MAP00340_Histidinemetabolism.txt
c27U 1 33_probes.txt
MAP00280_Valineleucineandisoleucinede
gradation.txt
c23U 1 33_probes.txt
c6_U1 33_probes.txt
mitochondrHG-U133Aprobes.txt
MAPOO140C21_Steroidhormonemetabolism
.txt
MAP00740_Riboflavinmetabolism.txt
HumFbSerumEarlyTF.txt
MAP00562_Inositol-phosphate-metabolism.txt
MAP00480_Glutathionemetabolism.txt
c1 2U1 33_probes.txt
MAP00010_GlycolysisGluconeogenesis.txt
clusteriLPSmouseurinary.txt
ROSHG-U1 33A-probes.txt
MAPO3030_DNA-polymerase.txt
c9_U1 33_probes.txt
MAP00380_Tryptophan-metabolism.txt
MAP00380_Tryptophan-metabolism-.txt
c20U 1 33_probes.txt
MAP00632_Benzoatedegradation.txt
c34U 1 33_probes.txt
MAP00790_Folate-biosynthesis.txt
HumFbSerumCoagHemo.txt
inflammatory.txt
c15_U133_probes.txt
humanmitoDB_6_2002_HG-U133A-probes.txt
MAP00625_Tetrachloroethene-degradation.txt
c8_U1 33_probes.txt
MAP00521_Streptomycin-biosynthesis.txt
c10_U133_probes.txt
MAP00720_Reductivecarboxylate-cycleCO2
_fixation.txt
ci_U133_probes.txt
c30U 1 33_probes.txt
MAP0031 0_Lysine-degradation.txt
c1 6_U 1 33_probes.txt
Enrichment
Score
321.0
310.3
308.1
304.6
301.7
283.6
278.6
254.7
252.7
240.8
238.7
237.6
228.1
227.3
220.3
219.5
217.8
217.1
210.3
209.7
209.1
209.1
205.8
202.7
196.4
194.0
190.9
188.7
187.6
187.2
186.4
185.7
182.8
180.4
179.2
179.1
177.9
175.1
175.0
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P value
1st iter.
0.001
0.014
0.018
0.003
0.016
0.008
0.013
0.01
0.005
0.002
0.006
0.008
0.014
0.002
0.008
0.006
0.007
0.007
0.002
0.014
0.003
0
0.004
0.007
0.006
0.001
0.005
0.006
0.013
0.018
0
0.012
0.001
0.002
0.003
0.016
0.008
0.001
0.008
P value
2nd iter.
0.003
0.015
0.018
0.004
0.016
0.011
0.01
0.017
0.01
0.006
0.008
0.002
0.006
0.002
0.008
0.014
0.006
0.004
0.006
0.018
0
0
0.003
0.006
0.005
0.002
0.006
0.008
0.007
0.015
0
0.007
0
0.007
0.003
0.011
0.007
0.003
0.006
P value
3rd iter.
0.007
0.016
0.018
0.004
0.017
0.01
0.012
0.014
0.009
0
0.004
0.007
0.011
0.005
0.006
0.011
0.008
0.006
0.001
0.014
0.001
0
0.003
0.003
0.013
0.004
0.007
0.009
0.015
0.016
0
0.009
0
0.011
0.001
0.008
0.004
0.002
0.004
c26_Ul 33_probes.txt
MAP00830_Retinolmetabolism.txt
GO_0005739_HG-U1 33A-probes.txt
c1 9_Ul 33_probes.txt
MAP00031_Inositolmetabolism.txt
c17_Ul33_probes.txt
MAP00530_Aminosugarsmetabolism.txt
c5_U133_probes.txt
MAP00440_Aminophosphonatemetabolism.txt
MAP00460_Cyanoaminoacidmetabolism.txt
MAP00360_Phenylalanine metabolism.txt
ECMconstituentconferring-elasticity.txt
ECM_structuralconstituentconferring-compre
ssionresistance.txt
INSHG-U 1 33A-probes.txt
MAP00020_Citrate-cycleTCA-cycle.txt
c32_U1 33_probes.txt
MAP00522_Erythromycin-biosynthesis.txt
HumFbSerumCholBiosyn.txt
c24_U1 33_probes.txt
cluster3_LPSmouseurinary.txt
c7_U 133probes.txt
MAP00361 gammaHexachlorocyclohexane_d
egradation.txt
GLUCOHG-U 1 33A-probes.txt
GLYCOLHG-U 1 33A-probes.txt
clusterl3_LPSmouseurinary.txt
MAPOO220_Urea-cycle-andmetabolismof_a
mino-groups.txt
MAP00630_Glyoxylateand dicarboxylate-met
abolism.txt
clusterl2_LPSmouseurinary.txt
MAP00071_Fafty-acid-metabolism.txt
MAP0051 1_N_Glycan-degradation.txt
MAP001 50_Androgen-and-estrogenmetabolis
m.txt
MAP00251 Glutamate metabolism.txt
MAP00072_Synthesis-and-degradationofket
onebodies.txt
KETHG-U1 33A-probes.txt
MAP00051_Fructoseandmannosemetabolis
m.txt
MAP00053_Ascorbateand_aldaratemetabolis
m.txt
MAP00631_1_2_Dichloroethanedegradation.tx
t
c18_Ul33_probes.txt
cO_Ul33_probes.txt
MAP00512_0_Glycans.biosynthesis.txt
c21_Ul33_probes.txt
cluster7_LPS_mouse_urinary.txt
MAP0041 0_betaAlaninemetabolism.txt
171.4
169.3
168.9
167.6
166.5
166.5
166.0
165.5
165.4
165.4
164.8
164.8
164.8
163.5
161.7
159.7
159.1
158.7
156.6
154.1
154.1
153.1
151.5
149.3
147.5
147.1
147.0
146.7
143.5
141.7
140.8
140.4
139.1
139.1
135.9
135.8
135.8
134.9
134.8
133.9
133.5
132.9
130.4
0.008
0
0.001
0.011
0
0.003
0.001
0.013
0
0
0.003
0
0
0.009
0.001
0.008
0.001
0.001
0.014
0.002
0.068
0.003
0
0
0.002
0.005
0
0.004
0.017
0
0
0
0.008
0
0
0.006
0
0
0.007
0.002
0.001
0
0
0.013
0.002
0.069
0.005
0.002
0.004
0.006
0.006
0
0.003
0.009
0
0
0.002
0.014
0
0
0.005
0
0
0.009
0.003
0.003
0.001
0.001
0.014
0.006
0.065
0.003
0.002
0.003
0.003
0.006 0.001 0.002
0.002
0.004
0.011
0.001
0.001
0.003
0.014
0.003
0.001
0.006
0.015
0.005
0.006 0.004 0.007
0.002 0.004 0.001
0 0.002
0.006 0.003
0
0.005
0 0.003 0.001
0
0
0.032
0.014
0
0.002
0.006
0.002
0
0
0.034
0.012
0.001
0
0.005
0.002
0
0
0.023
0.025
0.001
0.001
0.004
0.001
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cluster9_LPSmouseurinary.txt
MAP00770_PantothenateandCoA-biosynthe
sis.txt
c25_U1 33_probes.txt
MAP00940_Flavonoidsstilbeneandjlignin-bio
synthesis.txt
MAP00760_Nicotinateandnicotinamidemeta
bolism.txt
c2_U133_probes.txt
GLYCOGENHG-1 33Aprobes.txt
MAP001 30_Ubiquinone-biosynthesis.txt
PYRHG-U 1 33Aprobes.txt
MAP00640_Propanoate-metabolism.txt
FAHG-U 1 33A-probes.txt
MAP00030_Pentose-phosphate-pathway.txt
c22_U133_probes.txt
MAP00600_Sphingoglycolipid-metabolism.txt
c33_U 1 33_probes.txt
c31_U133_probes.txt
MAP00750_VitaminB6_metabolism.txt
MAP00620_Pyruvatemetabolism.txt
MAP0071OCarbon_fixation.txt
cluster4_LPSmouse_urinary.txt
MAP0051O0_N_Glycans-biosynthesis.txt
c35_U133_probes.txt
MAP00970_Aminoacyl tRNA biosynthesis.txt
MAP00062_Fatty-acid-biosynthesis-path_2.txt
inflammatory-mechanical.txt
MAP00052_Galactosemetabolism.txt
MAP00471_D_Glutamine-andD-glutamate_m
etabolism.txt
c11_U1 33_probes.txt
OXPHOSHG-U1 33A-probes.txt
MAP00570_Sphingophospholipid-biosynthesis.
txt
MAP00260_Glycineserineandthreoninemet
abolism.txt
MAP00960_AlkaloidbiosynthesisI I.txt
MAP00643_Styrene-degradation.txt
MAP00350_Tyrosinemetabolism.txt
MAP00533_Keratansulfate biosynthesis.txt
perception-of-pain-sensoryjransductuonof_
mechanicalstimulus.txt
sensory-perception-of-mechanicalstimulus.txt
cluster2_LPSmouse_urinary.txt
MAP00252_Alanineandaspartate-metabolis
m.txt
MAP00330_Arginine-and-proline-metabolism.t
xt
MAP00580_Phospholipid-degradation.txt
MAP00650_Butanoatemetabolism.txt
MAP00450_Selenoaminoacidmetabolism.txt
128.6
128.6
127.0
126.1
125.9
123.0
122.2
119.6
117.0
116.2
114.3
112.2
111.5
110.5
108.2
105.2
103.6
103.6
103.3
100.9
99.4
98.5
98.4
98.0
97.7
97.7
0.006 0.006 0.005
0
0.008
0
0.012
0
0.006
0 0.001 0.001
0.003
0.062
0.002
0.001
0.003
0.001
0.008
0.003
0.002
0.007
0.007
0.009
0.003
0.002
0.005
0.006
0.006
0.007
0.01
0.002
0.008
0.002
0.001
0.002
0.033
97.0
96.6
96.4
93.8
92.4
89.1
88.0
87.9
86.7
85.7
85.7
85.5
85.1
83.2
82.8
81.0
80.5
0
0.003
0.004
0.001
0.004
0.002
0.002
0
0.006
0.005
0.063
0.002
0
0
0.004
0.005
0.003
0.003
0.004
0.011
0.008
0.002
0.002
0.013
0.004
0.002
0.01
0.016
0.002
0.004
0
0.002
0.005
0.039
0.003
0.063
0.001
0.002
0.005
0.001
0.004
0.003
0.004
0.006
0.012
0.005
0.002
0.002
0.006
0
0.004
0.008
0.014
0.001
0.018
0.001
0.001
0.006
0.027
0
0.001
0.002
0.001
0.004
0.003
0.002
0
0.004
0
0.002
0.001
0.002
0.003
0.006
0.005
0
0.002
0.003 0.001 0.005
0.004
0.008
0.003
0.001
0.007
0.009
0.004
0
0.006
0.004
0.006
0.001
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c1 3_U1 33_probes.txt
MAP00561_Glycerolipid-metabolism.txt
MAP03020_RNA-polymerase.txt
MAP00240_Pyrimidine metabolism.txt
MAP00300_Lysine-biosynthesis.txt
MAP00230_Purinemetabolism.txt
MAP00670_Onecarbonpool-byjolate.txt
c14_U133_probes.txt
MAP00120_Bileacidbiosynthesis.txt
cluster6_LPSmouseurinary.txt
cluster1 1_LPSmouseurinary.txt
cluster5_LPSmouseurinary.txt
MAP00400_Phenylalaninejtyrosine-andjtrypto
phan-biosynthesis.txt
MAP00601_Blood-group-glycolipid-biosynthes
islactseries.txt
MAP00272_Cysteinemetabolism.txt
MAP00860_Porphyrin-and-chlorophyll-metabo
lism.txt
MAP00472_D_Arginine-and_D_ornithinemeta
bolism.txt
MAP001 00_Sterol biosynthesis.txt
MAP00532_ChondroitinHeparan-sulfatebios
ynthesis.txt
MAP00271_Methioninemetabolism.txt
c29_U133_probes.txt
MAP00430_Taurineand-hypotaurinemetaboli
sm.txt
MAP00680_Methanemetabolism.txt
MAPOO602_Blood-group-glycolipid-biosynthes
isneolactseries.txt
MAP0091 0_Nitrogen-metabolism.txt
MAP00061_Fafty-acid-biosynthesis-pathl.txt
MAP00253_Tetracycline-biosynthesis.txt
MAP00520_Nucleotidesugars-metabolism.txt
MAP001 95_Photosynthesis.txt
MAP001 90_Oxidative-phosphorylation.txt
MAP001 93_ATP-synthesis.txt
MAPO3070_Typej I L-secretion-system.txt
MAP00603_Globosidemetabolism.txt
MAP00040_Pentoseand-glucuronateintercon
versions.txt
TCAHG-U 1 33Aprobes.txt
clusterl4_LPSmouseurinary.txt
MAP00531_Glycosaminoglycan-degradation.txt
clusteri5_LPSmouseurinary.txt
MAP00290_Valineleucineandisoleucinebio
synthesis.txt
MAP00500_Starchandsucrosemetabolism.t
xt
c4_U133_probes.txt
c28U 1 33-probes.txt
0.002
0.012
0.001
0.005
0
0.006
0.001
0.012
0.002
0.001
0.006
0.01
79.5
79.4
79.4
79.3
77.2
76.5
74.5
74.4
72.3
72.1
71.8
71.5
71.2
68.8
64.2
63.8
59.2
56.3
52.5
51.9
51.9
51.3
50.2
49.9
46.5
41.1
41.1
36.9
35.2
34.2
34.1
34.1
33.9
33.0
32.9
32.1
27.3
26.8
25.9
25.7
21.8
21.0
0.005
0.002
0.003
0.003
0
0.005
0.001
0.004
0.001
0.001
0.008
0.006
0.004
0.004
0.004
0.007
0.001
0.006
0
0.005
0.004
0.002
0.009
0.007
0.009 0.005 0.008
0.005 0.004
0.001 0.006
0.003
0
0.001 0.003 0.008
0
0.022
0.001
0
0.008
0
0.014
0.003
0.003
0.005
0
0.024
0.007
0.002
0.006
0.007 0.005 0.005
0.001 0.003 0.001
0.006
0.004
0
0
0
0.005
0.01
0.006
0
0.006
0.004
0.014
0.002
0.006
0.009
0.001
0
0.011
0.001
0.008
0.006
0
0
0
0.004
0.006
0.004
0
0.007
0.006
0.008
0.002
0.002
0.006
0
0.001
0.013
0.004
0.005
0.003
0
0
0
0.001
0.005
0.004
0
0.002
0.005
0.003
0.006
0.001
0.006
0
0
0.007
0.006
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clusterl_LPSmouseurinary.txt
MAP00590_Prostaglandin_andleukotriene_me
tabolism.txt
MAP00780_Biotinmetabolism.txt
MAP00920_Sulfurmetabolism.txt
MAP00900_Terpenoid-biosynthesis.txt
MAP00950_Alkaloidbiosynthesisj.txt
19.1
16.8
12.1
9.2
9.0
5.6
0.007 0.01 0.012
0.002 0.011
0 0.001
0.001 0.002
0.019 0.016
0.002 0.004
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0.001
0.002
0.002
0.016
0.002
Appendix
Up regulated ES with P values
Gene Set
responsetomechanicalstimulus.txt
c26_U133_probes.txt
c6_U1 33_probes.txt
c3_U1 33_probes.txt
HumFbSerumEarlyTF.txt
OXPHOSHG-U 1 33Aprobes.txt
c27_U133_probes.txt
mitochondr_HG-U 1 33A-probes.txt
MAP0071OCarbon_fixation.txt
c14_U133_probes.txt
c30U 1 33_probes.txt
c1 8U1 33_probes.txt
c16_U133_probes.txt
MAP00950_Alkaloidbiosynthesisj.txt
MAPO3020_RNA-polymerase.txt
c5_U133_probes.txt
c33_U133_probes.txt
c20_U133_probes.txt
GLYCOLHG-U1 33A-probes.txt
ROSHG-U1 33Aprobes.txt
MAP00480_Glutathionemetabolism.txt
MAP00430_Taurineand-hypotaurinemetabolism.txt
MAP00230_Purinemetabolism.txt
c10_U133_probes.txt
c12_U133_probes.txt
MAP00361 gammaHexachlorocyclohexane-degradation.txt
MAP00251_Glutamatemetabolism.txt
MAP00740_Riboflavinmetabolism.txt
c32U 1 33_probes.txt
c17_U133_probes.txt
c19_U133_probes.txt
MAP00940_Flavonoidsstilbeneandjlignin-biosynthesis.txt
MAP00970_Aminoacyl-tRNA-biosynthesis.txt
MAP00030_Pentose-phosphate-pathway.txt
MAP00010_GlycolysisGluconeogenesis.txt
MAP001 90_Oxidative-phosphorylation.txt
c8_U1 33_probes.txt
MAP00031_Inositolmetabolism.txt
MAP00440_Aminophosphonatemetabolism.txt
MAP00460_Cyanoaminoacidmetabolism.txt
ECMconstituentconferring-elasticity.txt
ECMstructuralconstituentconferring-compressionresistance.txt
c 11U1 33_probes.txt
c29_U133_probes.txt
Enrichment
Score
560.2
415.6
343.6
336.8
335.1
328.9
289.0
283.7
274.4
265.8
262.2
259.0
253.7
249.4
249.1
244.7
244.3
239.7
223.9
218.6
216.9
211.9
210.6
208.0
205.4
204.4
202.6
202.1
202.0
200.6
197.8
192.8
185.4
184.4
183.3
182.9
181.8
172.0
171.5
171.5
171.3
171.3
169.0
168.1
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P value
0.085
0.014
0.023
0.003
0
0.131
0
0.018
0.004
0.002
0.001
0.045
0.002
0
0
0
0
0.003
0
0
0.001
0.006
0.001
0.006
0.002
0.005
0.001
0
0.002
0.001
0.004
0
0.009
0.002
0.001
0
0.019
0
0
0
0
0
0.001
0
c1 5U1 33_probes.txt 166.7 0
c9_Ul33_probes.txt 166.5 0.004
GLUCOHG-Ul33A-probes.txt 165.2 0.001
clusterl_LPSmouseurinary.txt 164.8 0
MAP00272_Cysteine-metabolism.txt 162.0 0
clusteriLPSmouseurinary.txt 161.5 0.003
MAP00240_Pyrimidine-metabolism.txt 160.8 0.003
MAP00900_Terpenoid-biosynthesis.txt 160.3 0.007
c35U1 33_probes.txt 154.2 0.001
MAP001 30_Ubiquinone-biosynthesis.txt 152.1 0.001
cluster1 1_LPSmouse_urinary.txt 151.6 0.009
MAP00040_Pentoseand-glucuronateinterconversions.txt 150.9 0
MAP001 95_Photosynthesis.txt 150.6 0.001
c28_U133_probes.txt 145.2 0
MAP00720_Reductivecarboxylate-cycleCO2_fixation.txt 143.3 0
MAP00400_Phenylalanineyrosine-andjtryptophan-biosynthesis.txt 141.9 0
MAPOO I93_ATP-synthesis.txt 140.1 0.001
MAP03070_Type_ I -secretion-system.txt 140.1 0
MAP00570_Sphingophospholipid-biosynthesis.txt 138.6 0
TCAHG-U1 33Aprobes.txt 138.0 0.005
MAP00561_Glycerolipidmetabolism.txt 135.6 0
HumFbSerumCoagHemo.txt 130.9 0.002
c21_U133_probes.txt 130.8 0.001
MAP00590_Prostaglandin_andleukotrienemetabolism.txt 128.0 0
MAP00780_Biotinmetabolism.txt 125.6 0
clusterl4_LPSmouseurinary.txt 125.4 0
PYRHG-U 1 33A-probes.txt 124.8 0
MAP00603_Globosidemetabolism.txt 122.7 0.002
MAP00472_DArginine-and_D_ornithinemetabolism.txt 122.3 0
MAP001 00_Sterol-biosynthesis.txt 120.5 0.038
c7_U 1 33probes.txt 119.1 0.098
MAP00260_Glycine-serineandthreoninemetabolism.txt 116.8 0.002
c31_U133_probes.txt 114.6 0.001
MAPO3030_DNA-polymerase.txt 112.9 0
MAP00630Glyoxylate-and dicarboxylate-metabolism.txt 111.9 0
c34_U133-probes.txt 111.6 0.003
inflammatory-mechanical.txt 111.1 0
MAP00532_ChondroitinHeparan-sulfate biosynthesis.txt 111.0 0
MAP00625_Tetrachloroethene-degradation.txt 110.6 0
cO_U133_probes.txt 110.3 0.026
MAP00300_Lysine-biosynthesis.txt 109.5 0
cluster5_LPSmouseurinary.txt 109.5 0
MAP00790_Folate-biosynthesis.txt 108.1 0
c1_Ul33_probes.txt 106.1 0.062
MAP00920_Sulfur_metabolism.txt 105.5 0.001
c13_1 33_probes.txt 105.2 0
MAP00471_D_Glutamine-andD-glutamate_metabolism.txt 99.7 0
MAP001 50_Androgen-and-estrogenmetabolism.txt 96.7 0
MAP00051_Fructoseandmannosemetabolism.txt 94.8 0.003
cluster6_LPSmouseurinary.txt 94.0 0
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MAP00360_Phenylalaninemetabolism.txt 89.2 0
MAP00860_Porphyrin-and-chlorophyll-metabolism.txt 89.0 0
MAP00522_Erythromycin-biosynthesis.txt 87.2 0
humanmitoDB_6_2002_HG-Ul33A-probes.txt 85.8 0.047
MAP00061_Fatty-acid-biosynthesis-path_1.txt 83.9 0
MAP00253-Tetracycline-biosynthesis.txt 83.9 0
c4_Ul33_probes.txt 81.5 0.013
c23U 1 33_probes.txt 80.2 0.002
GO_0005739_HG-U1 33A-probes.txt 78.0 0.007
MAP00643_Styrene-degradation.txt 77.3 0
MAP00252_Alanineand-aspartatemetabolism.txt 77.2 0.001
MAP00530_Aminosugarsmetabolism.txt 76.9 0
MAP00140_C21_Steroidhormonemetabolism.txt 73.3 0.001
MAP00290_Valineleucineandisoleucinebiosynthesis.txt 72.7 0.001
MAP00020_Citrate-cycleTCA-cycle.txt 72.5 0.003
MAP00580_Phospholipid-degradation.txt 70.5 0.001
hypoxia.txt 69.5 0.001
MAP00600_Sphingoglycolipid-metabolism.txt 69.3 0.002
MAP00380Tryptophan-metabolism.txt 66.6 0.002
MAP00380_Tryptophan-metabolism-.txt 66.6 0
MAP00511 N_Glycan-degradation.txt 64.4 0.001
inflammatory.txt 63.2 0.003
MAP00062_Fatty-acid-biosynthesis-path_2.txt 62.4 0.006
INS_HG-U 1 33A-probes.txt 61.4 0.009
cluster4_LPSmouseurinary.txt 60.8 0.002
MAP0091 0_Nitrogen-metabolism.txt 56.5 0
MAP00650_Butanoatemetabolism.txt 56.3 0.004
cluster2_LPSmouseurinary.txt 55.8 0
clusterl2_LPSmouseurinary.txt 53.3 0.002
MAP00531_Glycosaminoglycan-degradation.txt 52.0 0.008
MAPOO220_Urea-cycle-and metabolismofamino-groups.txt 51.3 0
c24_U133_probes.txt 50.5 0.015
MAP00350_Tyrosine-metabolism.txt 50.1 0.001
MAP00500_Starchandsucrosemetabolism.txt 50.1 0
MAP00533_Keratansulfate-biosynthesis.txt 46.3 0
MAP00520_Nucleotidesugars-metabolism.txt 44.1 0
MAP00450_Selenoaminoacidmetabolism.txt 44.0 0
cluster3_LPSmouseurinary.txt 41.1 0
MAP00052_Galactosemetabolism.txt 39.8 0
MAP00340_Histidinemetabolism.txt 39.4 0.005
cluster9_LPSmouseurinary.txt 37.5 0
c22U 1 33-probes.txt 37.4 0
HumFbSerumChol_Biosyn.txt 35.3 0
MAP00680_Methanemetabolism.txt 34.2 0
c2_Ul33_probes.txt 33.9 0.092
MAP00512_QGlycans-biosynthesis.txt 30.1 0
MAP00760_Nicotinateandnicotinamidemetabolism.txt 28.6 0.002
MAP00620_Pyruvate-metabolism.txt 26.6 0.001
MAP00770_PantothenateandCoA-biosynthesis.txt 26.2 0
MAPOO601 _Blood-group-glycolipid-biosynthesislactseries.txt 23.2 0.001
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MAP00750_VitaminB6_metabolism.txt 22.6 0
cluster1 5_LPSmouseurinary.txt 21.2 0.013
MAP00330_Arginine-and-proline-metabolism.txt 20.3 0.002
MAP005621Inositol_phosphate-metabolism.txt 16.5 0.005
MAP00071_Fatty-acid-metabolism.txt 14.4 0.013
MAPOO602_Blood-group-glycolipid-biosynthesisneolactseries.txt 13.5 0.004
MAP00120-Bileacidbiosynthesis.txt 12.2 0.013
KETHG-U1 33A-probes.txt 9.9 0
MAP00670_Onecarbon-pool-by-jolate.txt 7.9 0.003
MAP0041 0_betaAlaninemetabolism.txt 7.3 0
c25U 1 33_probes.txt 7.3 0.005
MAP00960_AlkaloidbiosynthesisIl.txt 7.2 0
GLYCOGENHG-133Aprobes.txt 7.2 0
MAP00271_Methioninemetabolism.txt 7.1 0
MAP00521_Streptomycin-biosynthesis.txt 6.7 0.001
clusterl3_LPSmouseurinary.txt 4.4 0
MAP0031 OLysine-degradation.txt 4.2 0.001
MAP00830_Retinol metabolism.txt 4.0 0
MAP0051O0_NGlycans-biosynthesis.txt 4.0 0
MAP00640Propanoate-metabolism.txt 3.3 0.004
cluster7_LPSmouseurinary.txt 3.3 0.002
MAP00053_Ascorbateandaldaratemetabolism.txt 3.0 0
MAP00631_1_2_Dichloroethanedegradation.txt 3.0 0
MAP00632_Benzoatedegradation.txt 3.0 0.008
MAP00280_Valineleucineandisoleucinedegradation.txt 3.0 0.008
FAHG-U133A-probes.txt 2.2 0.015
perception-of-pain-sensoryjransductuon ofmechanicalstimulus.txt 1.4 0.001
sensory-perception-of-mechanicalstimulus.txt 1.4 0
MAP00072Synthesis-and-degradationofketonebodies.txt 1.4 0.002
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Appendix
Down regulated GSEA
Gene Set ES P value
MAP00280_Valineleucineandisoleucinedegradation.txt 346.6 0.008
MAP00340_Histidine-metabolism.txt 288.9 0.005
MAP0031 0_Lysine&degradation.txt 284.6 0
MAP00380_Tryptophan-metabolism.txt 274.2 0.002
MAP00380Tryptophan-metabolism-.txt 274.2 0
MAP00632_Benzoate-degradation.txt 270.5 0.01
hypoxia.txt 263.3 0
MAP00562_nositol_phosphate-metabolism.txt 261.8 0.004
MAP00052_Galactose metabolism.txt 242.5 0
MAP00521_Streptomycin-biosynthesis.txt 239.2 0.001
cluster7_LPSmouseurinary.txt 234.1 0
cluster15_LPSmouseurinary.txt 232.8 0.014
GLYCOGENHG-133Aprobes.txt 227.8 0
FAHG-U133A-probes.txt 225.9 0.011
MAP00072_Synthesis-and-degradationofketonebodies.txt 219.9 0.001
MAP0041ObetaAlaninemetabolism.txt 216.2 0.003
MAP00071_Fafty-acid-metabolism.txt 210.4 0.027
MAP0051O0_N_Glycans-biosynthesis.txt 209.1 0
clusterl3_LPSmouseurinary.txt 207.1 0.001
c23U 1 33_probes.txt 205.6 0.003
MAPOO602_Blood-group-glycolipid-biosynthesisneolactseries.txt 203.3 0.002
MAP00670_Onecarbon-pool-byfolate.txt 202.3 0.001
HumFbSerumCholBiosyn.txt 200.3 0
MAP00640-Propanoate-metabolism.txt 198.9 0.005
c22U 1 33_probes.txt 196.6 0
MAP001 40_C21_Steroidhormonemetabolism.txt 193.0 0.001
MAP00650_Butanoate metabolism.txt 183.0 0.006
MAPO01 20_Bileacidbiosynthesis.txt 179.0 0.008
MAP0091 0_Nitrogen-metabolism.txt 176.5 0.001
MAP00750_VitaminB6_metabolism.txt 174.1 0.001
MAP00830_Retinolmetabolism.txt 172.3 0
c25U 1 33_probes.txt 171.3 0.003
MAP00053_Ascorbate and aldarate metabolism.txt 166.2 0
MAP00631_1_2_Dichloroethanedegradation.txt 166.2 0
inflammatory.txt 162.9 0.004
MAP00220_Urea-cycle-andmetabolismofamino-groups.txt 162.1 0
MAP00760_Nicotinateandnicotinamidemetabolism.txt 160.5 0.001
MAP00360_Phenylalaninemetabolism.txt 159.4 0
c34U 1 33_probes.txt 158.8 0.003
c2_U133_probes.txt 154.3 0.075
cluster9_LPSmouseurinary.txt 153.7 0
MAP00580Phospholipid-degradation.txt 153.6 0.003
GO_0005739_HG-U 1 33A-probes.txt 152.7 0.008
MAPOO601_Blood-group-glycolipid-biosynthesislactseries.txt 151.7 0.002
MAP00603_Globosidemetabolism.txt 151.7 0.002
149
clusterl2_LPSmouseurinary.txt 151.5 0.003
MAP00770_PantothenateandCoA-biosynthesis.txt 150.2 0
MAP001 93_ATP-synthesis.txt 149.7 0
MAP03070_TypejI I secretion-system.txt 149.7 0
c24_1 33_probes.txt 148.6 0.01
MAP00271_Methioninemetabolism.txt 146.7 0
MAP00330_Arginine-and-proline-metabolism.txt 144.5 0.003
MAP00533Keratansulfate-biosynthesis.txt 143.7 0
MAP0051 1_NGlycan-degradation.txt 142.3 0
KETHG-U1 33A-probes.txt 141.0 0.001
MAP00061 Fatty-acid-biosynthesis-pathl.txt 138.4 0
MAP00253_Tetracycline-biosynthesis.txt 138.4 0
MAP00960_AlkaloidbiosynthesisIl.txt 138.3 0
MAP00062_Fafty-acid-biosynthesis-path_2.txt 137.6 0.006
humanmitoDB_6_2002_HG-U133A-probes.txt 137.2 0.039
cluster2_LPSmouse_urinary.txt 134.0 0
HumFbSerumCoagHemo.txt 132.6 0.003
MAP00600_Sphingoglycolipid-metabolism.txt 130.2 0
INS_HG-U1 33A-probes.txt 126.9 0.009
MAP00520_Nucleotidesugars-metabolism.txt 125.4 0
MAP00531_Glycosaminoglycan-degradation.txt 123.5 0.002
cluster4_LPSmouseurinary.txt 123.2 0
MAPO3030_DNA-polymerase.txt 121.8 0.001
cluster3_LPSmouseurinary.txt 121.7 0.001
c1_Ul33_probes.txt 120.4 0.047
MAP00530_Aminosugarsmetabolism.txt 120.3 0
c4_U133_probes.txt 118.4 0.014
perception-of-pain-sensory-transductuon ofmechanicalstimulus.txt 116.9 0
sensory-perception-of-mechanicalstimulus.txt 116.9 0
MAP001 95_Photosynthesis.txt 116.3 0.001
MAP00350_Tyrosine-metabolism.txt 115.5 0.001
MAP00920_Sulfurmetabolism.txt 113.0 0.004
MAP00020_Citrate-cycleTCA-cycle.txt 110.6 0.002
MAP00450_Selenoaminoacidmetabolism.txt 109.8 0
MAP00532_ChondroitinHeparan-sulfate biosynthesis.txt 106.4 0
MAP00512_QGlycans-biosynthesis.txt 105.7 0.001
MAP00290_Valineleucineandisoleucinebiosynthesis.txt 105.5 0
MAP00790_Folate-biosynthesis.txt 105.1 0
MAP00500_Starchandsucrosemetabolism.txt 102.3 0
MAP001 00_Sterol-biosynthesis.txt 100.9 0.03
MAP00522_Erythromycin-biosynthesis.txt 99.8 0
MAP00620_Pyruvate-metabolism.txt 98.4 0
MAP00272_Cysteine-metabolism.txt 98.1 0
c1 5U1 33-probes.txt 97.0 0
MAP00010_GlycolysisGluconeogenesis.txt 96.1 0
MAP001 50_Androgenand-estrogenmetabolism.txt 95.9 0.001
MAP00040_Pentoseand-glucuronateinterconversions.txt 95.5 0
MAP00720_Reductivecarboxylate-cycleCO2_fixation.txt 94.9 0
MAP00680_Methanemetabolism.txt 93.1 0
MAP00252_Alanineand-aspartatemetabolism.txt 92.4 0.001
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clusterl_LPSmouseurinary.txt 92.0 0
MAP00625-Tetrachloroethene-degradation.txt 90.1 0
MAPO3020-RNA-polymerase.txt 89.2 0
c7_U133_probes.txt 88.6 0.096
c27U 1 33_probes.txt 87.4 0
MAP00630_Glyoxylateand dicarboxylate-metabolism.txt 83.9 0
c9_U133_probes.txt 82.7 0.004
MAP00900_Terpenoid-biosynthesis.txt 82.5 0.001
MAP00471__D_Glutamine-andD-glutamatemetabolism.txt 81.0 0
MAP00860_Porphyrin-and-chlorophyll-metabolism.txt 80.8 0
TCAHG-U1 33A-probes.txt 78.1 0.006
clusterl4_LPSmouseurinary.txt 76.5 0
c29_U133_probes.txt 76.4 0
MAP00051_Fructoseandmannosemetabolism.txt 76.0 0
mitochondrHG-U133Aprobes.txt 75.0 0.016
c35U 1 33_probes.txt 74.4 0
MAP00643_Styrene-degradation.txt 74.4 0
MAP00260_Glycine-serineandthreoninemetabolism.txt 74.4 0.001
inflammatory-mechanical.txt 74.3 0
c21_U133_probes.txt 72.9 0.003
MAP00780_Biotinmetabolism.txt 71.9 0
MAP00400_Phenylalanine-tyrosine-andjtryptophan-biosynthesis.txt 71.3 0
c28U 1 33_probes.txt 69.0 0.001
MAP00430_Taurineand-hypotaurinemetabolism.txt 68.5 0.004
cluster1_LPSmouseurinary.txt 66.6 0
MAP00300_Lysine-biosynthesis.txt 62.2 0.005
c1 9U 1 33_probes.txt 59.5 0
MAP00240OPyrimidine metabolism.txt 59.5 0.005
MAP001 30_Ubiquinone-biosynthesis.txt 58.7 0
c10U133_probes.txt 56.1 0.01
MAP00230OPurinemetabolism.txt 55.2 0.004
MAP00472_DArginine-and_D_ornithinemetabolism.txt 54.1 0
c32U 1 33_probes.txt 54.1 0
MAP00740ORiboflavinmetabolism.txt 52.6 0
c30U 1 33_probes.txt 51.9 0.001
MAP00590OProstaglandin_andleukotrienemetabolism.txt 51.9 0
cO_U133_probes.txt 51.3 0.042
cluster6_LPSmouseurinary.txt 50.2 0
ROSHG-U1 33A-probes.txt 49.6 0
MAP001 90_Oxidative-phosphorylation.txt 49.5 0
c8_U133_probes.txt 47.7 0.027
MAP00561_Glycerolipidmetabolism.txt 47.5 0.001
clusteri 1 _LPSmouse_urinary.txt 47.2 0.009
c3_U133_probes.txt 46.7 0
MAP00480_Glutathionemetabolism.txt 46.4 0
MAP00950AlkaloidbiosynthesisjI.txt 46.0 0
c20U 1 33_probes.txt 44.9 0.002
c1 2U1 33_probes.txt 44.1 0
cluster5_LPSmouseurinary.txt 43.5 0.001
c1 7U1 33-probes.txt 41.8 0.001
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c6_U1 33probes.txt 41.1 0.025
c31 U 1 33probes.txt 38.1 0
MAP00570_Sphingophospholipid-biosynthesis.txt 37.8 0
c16_U133_probes.txt 32.0 0.004
GLUCOHG-U1 33A-probes.txt 26.5 0
MAP00970AminoacyltRNA-biosynthesis.txt 26.3 0.013
c33U 1 33_probes.txt 25.4 0
MAP00940_Flavonoidsstilbeneandjlignin-biosynthesis.txt 21.8 0
c1 3U1 33_probes.txt 20.6 0
PYRHG-U1 33A-probes.txt 19.6 0.003
c5_U1 33_probes.txt 19.6 0.002
c14_U133_probes.txt 18.3 0.002
MAP00361 gammaHexachlorocyclohexane-degradation.txt 16.1 0.004
OXPHOSHG-U1 33Aprobes.txt 15.2 0.131
MAP0071 0_Carbonfixation.txt 13.9 0.002
c1 8U1 33_probes.txt 13.8 0.035
G LYCOLHG-U 1 33A-probes.txt 13.5 0
MAP00030_Pentose-phosphate-pathway.txt 11.3 0.001
c 11 U133_probes.txt 9.5 0.001
HumFbSerumEarlyTF.txt 7.2 0.003
c26U1 33_probes.txt 7.0 0.029
MAP00251_Glutamatemetabolism.txt 5.8 0.001
ECMconstituentconferring-elasticity.txt 5.1 0
ECMstructuralconstituentconferring-compressionresistance.txt 5.1 0
MAP00440_Aminophosphonatemetabolism.txt 4.8 0
MAP00460_Cyanoaminoacidmetabolism.txt 4.8 0
responsejto-mechanicalstimulus.txt 4.4 0.108
MAP00031_Inositolmetabolism.txt 4.3 0
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Appendix
Microchip preparation and RNA extraction protocol (from Travis Burleson at the
Children's Hospital microarray facility)
Introduction
Microarray technology has greatly enhanced and accelerated the ability to analyze
relevant changed that occur in biological samples. Affymetrix has long been the gold
standard in this field. They are currently producing their most recent chip to analyze the
entire human genome on a single array. The GeneChip Human Genome U133 Plus 2.0
array provides comprehensive coverage of the transcribed human genome. It consists of
over 54,000 probe sets and 1,300,000 distinct oligonucleotide features. The sequences
for the probe sets were selected from GenBank, dbEST, and RefSeq databases, while the
sequence clusters were created from the UniGene database.
The scientists in the Microarray Facility at Children's Hospital Boston are experts in
Affymetrix technology. With the most recent scanners and analysis programs, as well as
years of experience, they provide excellent an excellent group to have biological samples
analyzed.
Equipment and Capacity
The Microarray Core Facility owns two GeneChip Hybridization Ovens, three GeneChip
Fluidics Station 450s, and a GeneChip Scanner 3000 with Autoloader. At capacity, the
core can extract samples in batches of 6 and perform the reverse transcription/invitro
transcription reactions in batches of 6 to 12. Up to 24 chips can be analyzed per week.
Tissue Criteria
The single most important determinant in the success of a GeneChip assay is the quality
of the RNA. Differential degradation of RNA can lead to erroneous conclusions about
both the relative and absolute mRNA levels in the specimens. The quality of RNA is
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directly related to proper tissue handling procedures which will be out of the control of
the Microarray Core Facility. We expect the tissue samples will meet the following:
1. The tissue samples will have been frozen in liquid nitrogen within one hour of
being taken.
2. The tissue samples will be predominantly skeletal muscle.
3. The size of each tissue sample will be 70mg or larger.
4. All tissue samples will be shipped on dry ice and not have undergone multiple
freeze/thaw cycles.
Upon arrival, we will store the tissue samples in a -80C freezer until being extracted. If a
tissue passes visual inspection, it will undergo total RNA isolation (outlined in the RNA
isolation section). After the total RNA is isolated, it will be analyzed on a 1% agarose
gel for quality purposes. The gel will be employed to determine if the 28S: 18S ribosomal
bands have a ratio of 2:1. If the gel fails to meet our criteria by not having a 2:1 ratio, or
by containing any other anomalies, the sample will be re-extracted. Following this
second extraction, the total RNA sample will be analyzed again on a 1% agarose gel.
RNA Isolation
Patient tissue samples weighing 70-120 mg will be homogenized in 1 ml of ice cold
Trizol (Life Technologies, Rockville, MD) for 30 seconds at room temperature then
centrifuged at 100 C to remove cell debris. DNA and proteins will be removed by
chloroform:isoamyl alcohol (49:1) extraction, and Isopropanol, sodium citrate (0.8M) and
sodium chloride (1.2M) will be used for RNA precipitation. RNA concentration is
measured using a spectrophotometer and RNA quality will be evaluated by running 1 pg
of RNA on a 2% agarose gel.
Target (labeled cRNA) Preparation
Good quality total RNA is the necessary starting material to obtain labeled RNA.
Approximately 7 pg of total RNA will be used for cDNA synthesis (Superscript II kit,
Life Technology). Biotin labeled cRNA is produced through in vitro transcription using
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the cDNA of the previous reaction (BioArray High Yield RNA transcript Labeling kit,
Enzo, Farmingdale, NY).
The biotin-labeled RNA will be analyzed on a spectrophotometer to determine
concentration and purity. Final RNA output should be greater that 20ug and have a
260/280 ratio of 1.8-2.2. 20ug of the cRNA is then fragmented in the presence of heat
and Mg++, before a hybridization cocktail is created.
Hybridization Cocktail
Hybridization Coctails will be prepared according to the procedure outlined by
Affymetrix. In brief, 15ul of fragmented biotin-labled cRNA, Control Oligonucleotide
B2, Hybridization Controls (bioB, bioC, bioD, and cre), BSA, Herring Sperm DNA, and
buffer will be mixed.
Array Hybridization, Wash, Stain and Scan (HWSS):
200ul of the Hybridization Coctail is hybridized to an array for 16 hours at 450 C and
60RPM. The array is then washed and stained in a GeneChip Fluidics Station 450. The
staining protocol is a antibody amplification. The first stain with streptavidin-
phycoerythrin is followed by an antibody amplification with Goat IgG and biotinylated
antibody. The final stain is with streptavidin-phycoerythin.
The washed and stained chip will be scanned on an Affymetrix GeneChip Scanner 3000.
Array Data Analysis and Quality Control Standards
Scanned chip images will be analyzed using GCOS v 1.1 and analyzed for quality. The
parameters that determine good quality data include: the 3'/5' ratio of housekeeping
genes B-Actin and GAPDH; Background values; Noise (Q) values; Scaling Factor
values; and Spiked Control values. We have outlined values that the data should adhere
to. The sample data should meet outlined values, but deviation in a quality control value
may not cause the sample to be discarded; rather the global quality will also be taken into
155
account. The Core will contact Wyeth about any data in question and make suggestions
about whether the sample is good or bad.
3'/5' ratio of housekeeping genes: This is a measure of the efficiency of the cDNA
synthesis reaction. Reverse transcriptase synthesizes cDNA starting from the 3'-end of an
mRNA and ending at the 5'-end. All Affymetrix arrays contain probes for the regions
corresponding to 3', middle and 5'-end of the house keeping genes such as GAPDH and
B-Actin. The ratio of signal intensity for 3' probes to that from 5' probes provides a
measure of the number of cDNA synthesis reactions that went to completion (full length
cDNA is synthesized). An ideal ratio would be 1 whereas a higher value indicates that
many cDNAs were started but did not go to completion. The 3'/5' ratio for these
housekeeping genes should be at most 3. If the ratio is above 3, the sample will be
resubmitted to Wyeth to ascertain if the sample should be used.
Using a reference experiment of 63 muscle biopsy samples extracted and labeled
according to the above outlined protocol and analyzed on U133A chips, we observe a B-
Actin average value of 1.45, and a GAPDH average value of 1.5. Although these values
are for U133A chips, we expect similar values using the U133 Plus 2.0 arrays.
Background values with standard deviation. Background value is a measure of the signal
intensity caused by autofluorescence of the array surface as well as nonspecific binding
of target or stain molecules (SAPE). The background values for all the arrays in one
experiment should be very similar to each other; otherwise comparison data may not be
accurate. Non-specific binding causes a low signal to noise ratio, which means that genes
for transcripts present at very low levels in the sample may incorrectly be called absent.
Thus, high background creates an overall loss of sensitivity in the experiment. Any
samples with a background value over 120 will be resubmitted to Wyeth to ascertain if
the data should be used.
Using a reference experiment of 63 muscle biopsy samples extracted and labeled
according to the above outlined protocol and analyzed on U133A chips, we observe a
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Background average value of 79.9. Although these values are for U133A chips, we
expect similar values using the U133 Plus 2.0 arrays.
Noise (0) value. Noise (Q value) results from small variations in the digitized signal
observed by the scanner as it samples the probe array's surface. It is measured by
examining pixel-to-pixel variations in background intensities. The noise value for all the
arrays in one experiment should be very similar to each other. Any samples with a Noise
(Q) value over 5 will be resubmitted to Wyeth to ascertain if the data should be used.
Using a reference experiment of 63 muscle biopsy samples extracted and labeled
according to the above outlined protocol and analyzed on U133A chips, we observe a
Noise (Q) average value of 3.02. Although these values are for U133A chips, we expect
similar values using the U133 Plus 2.0 arrays.
Scaling factor. The scaling factor provides a measure of the brightness of the array. The
"brightness" (image intensity) varies from array to array. Non-biological factors (amount
and quality of the cRNA, amount of stain or other experimental variation) can contribute
to the overall variability in hybridization intensities. In order to reliably compare data
from multiple arrays, it is essential that the intensity of the arrays be brought to the same
level. Scaling is a mathematical technique used by the Gene Chip Operating Software
(GCOS) to minimize differences in overall signal intensities between two or more arrays
thus allowing for more reliable detection of biologically relevant changes in the same
sample. GCOS calculates the overall intensity of an array by averaging the intensity
values of every probe set on the array with the exception of the top and bottom 2% of the
probe set intensities. The average intensity of the array is then multiplied by the Scaling
factor to bring it to an arbitrary Target Intensity value (usually 1500) set by the user.
Thus, scaling allows a number of experiments to become normalized to one Target
Intensity, allowing comparison between any two experiments. In a particular set of
experiment, the Scaling Factor value for all the arrays should be very close to each other
(within three-fold of each other). Any samples with a scaling value over 12 will be
resubmitted to Wyeth to ascertain if the data should be used.
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Using a reference experiment of 63 muscle biopsy samples extracted and labeled
according to the above outlined protocol and analyzed on U133A chips, we observe a
scaling average value of 9.44. Although these values are for U133A chips, we expect
similar values using the U133 Plus 2.0 arrays.
Presence of spiked control cRNAs: Bio-B, C, D and CRE serve as a controls for
hybridization and are spiked at the following concentrations: BioB: 1.5 pM, BioC: 5.0
pM, BioD: 25.0 pM, BioCRE: 100 pM. We specifically look at the average difference
values which should be present in increasing amounts, B being the least and CRE the
highest.
Microarray expression array protocol:
Whole frozen tissue samples are mixed with TRIzol reagent and homogenized
completely. This mixture is centrifuged for ten minutes at 4 c and then incubated at room
temperature for five minutes to dissociate nucleoprotein complexes. 200 piL of
chloroform is added, the sample is shaken to homogenize the solution, and is incubated at
room temperature for two minutes. The sample is then spun again in a centrifuge for 15
minutes at 4 c. The aqueous layer is extracted and to it is added 250 p.L of isopropyl
alcohol and 250 jiL of a salt solution containing sodium citrate and sodium chloride. The
sample is mixed thoroughly, incubated at room temperature for ten minutes and spun in a
centrifuge for ten minutes at 4 c. The supernatant is removed, the pellet is washed with
75% EtOH, and then resuspended in RNAse-free water.
Following extraction, the RNA is quantified and checked for purity on a
spectrophotometer. If the RNA is of sufficient quality and quantity, it then is used for the
synthesis of cDNA. 7 pg of the extracted RNA is used in this reaction. We use the
SuperScript Double Stranded cDNA Synthesis kit from Invitrogen for this reaction. This
kit contains all enzymes and reagents needed for the synthesis of double stranded cDNA.
This reaction takes between 3 and 4 hours (depending on set-up and clean-up time). The
product of this reaction is cleaned in a standard phenol-chloroform type extraction using
a phase-lock gel. To the resulting solution containing the double stranded cDNA is added
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2.5 volumes of 100% EtOH and 0.5 volumes of 7.5M ammonium acetate. This solution
is incubated at -20 c overnight to allow the cDNA to precipitate.
The precipitation is spun in a centrifuge and the pellet is cleaned in EtOH and
resuspended in Rnase-free water. This product is used in the next step: Invitro
Translation. For this reaction, we use the Bioarray biotin labeling kit from Enzo. This kit
synthesizes single stranded cRNA from the cDNA product produced in the last step. This
kit also incorporates the biotin labeled nucleotides necessary for hybridization. This kit
contains all necessary enzymes and reagents for the reaction. This reaction takes
approximately 4.5 hours (including preparation), which is followed by a clean-up using
the RNeasy kit supplied by Qiagen. This kit contains all necessary buffers and columns
for the process. This step takes approximately 0.5 hours. The resulting solution
containing the labeled cRNA is subjected to the same precipitation process as detailed
above.
Again, the precipitation is spun, washed, and resuspended. The cRNA is
quantified and checked for purity on a spectrophotometer. Approximately 20 pg of the
cRNA is used in the fragmentation step. The cRNA is added to a solution containing
magnesium acetate and potassium acetate. By a process of metal induced hydrolysis, the
cRNA is broken down into 35 - 200 bp fragments. This process takes 35 minutes and is
performed at 95 c. Following the fragmentation, other components, including BSA,
Herring Sperm DNA, and spike and housekeeping controls, are added to the cRNA to
form a 'Hybridization Cocktail'. This cocktail is then injected onto the array, hybridized
for 16 hours, and scanned. The hybridization cocktails can be used up to 5 times and can
last for up to a year if stored at -80 c.
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Appendix
Validation of the FEA using order of magnitude analysis
Order of Magnitude Analysis
The atmosphere imposes a uniform pressure of about 1 bar (or 105 Pa). The force
applied to a system is equal to the differential pressure (gage pressure) multiplied by the
surface area over which the pressure acts.
Think of a vacuum cup applied to a surface. Let us start evacuating the air from
the cup. If we have a good seal, no air will be allowed to come into the cup to replace the
air lost. Thus, because we have reduced the number of molecules in the system-and
assuming the temperature is allowed to stay constant, and that the cup is rigid such that
its volume is fixed, we see from the perfect gas law that the pressure in the system will
fall:
P1V=nRT .. .(1)
The '1' subscript refers to conditions before the evacuation of molecules. No subscript on
a variable implies that that variable is held fixed. Next after the decrease in pressure,
P2V=n 2RT ... (2)
The '2' subscript on variables refers to conditions after the evacuation of pressure.
Dividing (1) by (2), we obtain -=-i, or P2 = 2P, which says that as n2 goes down
P2 n2 n,
the pressure P2 decreases.
Force is nothing but the pressure times the area. Now the pressure always acts
normal to a surface. Since the pressure on the inside of the cup is lower than atmospheric
pressure, a lower force acts on this side. If the cup is rigid, as it is in this example, then
the difference in forces will be countered by the stresses set up in the cup wall. If
however, the system is allowed to be flexible, then the difference in pressures (and hence
forces) will cause the system to collapse, until we come to an equilibrium.
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In the equilibrium state, the difference in pressure still exists. This difference in
pressure is taken up by the stresses set up in the wound itself (as well as stresses in the
material making up the vac sponge). We thus see that the pressure differential causes the
vac sponge to collapse. However, the reduction in volume is not enough to cause the
pressure to become atmospheric inside the seal. Furthermore, the material of the vac
sponge itself is much less compliant than the wound bed (once the sponge has
compressed-before the compression, the overall vac sponge compliance is higher than
the wound). Thus, the wound now locally (between the pores that define the vac sponge)
rises.
Now let's see what kinds of stresses are set up-assuming a thin walled system
for the wound. This is a rough approximation, because the wound is not a thin walled
vessel. The thin wall approximation allows us to assume that the stresses in the wall are
uniform, so the results we obtain from this theoretical framework give us an order of
magnitude understanding and validation of the finite element results.
For a thin membrane acted on by an internal pressure, we equate the pressure
forces acting over the inside surface to the stresses acting over the wall thickness. Thus,
a27rrt = r 2 P1 , where Pi is the pressure differential applied to the wound, and r is the
radius of the pore of the vac sponge. a is the stress in the wound bed. Solving for a, we
Pr
obtain a = -, and putting in the values for our pressure-and assuming a thickness of
2t
about 1mm, we obtain for the stress an order of magnitude of a = 9,00OPa . Now we use
the modulus of elasticity of 50,00OPa to obtain the strain. This is, e = =18%, and this
E
is on the order of magnitude of the strain we obtained in our analyses.
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